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Glioblastoma multiforme (GBM) is the most aggressive and incurable primary 
brain tumor with a current median overall survival of approximately 14 months. Immune 
checkpoint-based therapy has demonstrated successes in solid tumors including 
melanoma and lung cancer increasing overall survival, however, it has not been 
successful in combating Central Nervous System (CNS) tumors.  Our studies seek to 
establish a successful checkpoint inhibitor-based immunotherapy model for treating 
GBM, and our central hypothesis is, synthetic ligands modulate CD200 activation 
receptors (CD200ARs) overriding the inhibitory effect mediated by CD200 binding to 
CD200IR.  
The CRISPR/Cas9 system was used to generate different murine raw264.7 
macrophages (MØs) cell lines expressing different combinations or a single CD200 
receptor. The resultant cell lines were stimulated with the synthetic ligand, and the effects 
of this binding were studied.  
The main achievements of this research were to demonstrate that CD200ARs 
stimulated by synthetic peptide-binding couples with DAP10, and stimulates downstream 
activation of phosphatidylinositol 3-kinase, Vav1, cJUN, and ERK1/2. Second, 
CD200ARs form complexes (CD200ARs 2&3) to interact with the peptide ligands to 
optimize the biological function of macrophages. Third, the signals initiated by 
CD200ARs/DAP10 induce cytokine secretion and immune activation that results in 
tumor control.  
 
 v 
Our research reveals the signaling pathway of the CD200 immune checkpoint that 
leads to activation rather than suppression of immune cells and improves the response of 
GBM to vaccine-based immunotherapy.  
 
 vi 
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1.1 General Aspects of Glioblastoma  
1.1.1 Glioblastoma Epidemiology 
Glioblastoma (GBM) is the most common and aggressive malignant primary 
brain tumor.  GBM has the poorest overall survival with a < 5% 5-year survival time and 
median survival time of 14-15 months despite standard of care therapy, making this 
disease an important public health issue. (Aldape et al. 2003; ICBTRotUS 2012; Cagney 
and Alexander 2017). GBM accounts for 45.2% of malignant primary brain and CNS 
tumors, 54% of all gliomas, and 16% of all primary brain and CNS tumors (Tran and 
Rosenthal 2010). Treatment is multimodal, with safe surgical resection followed by 
radiation therapy (RT) and concurrent Temozolomide (TMZ) chemotherapy (Stupp et al. 
2005; Stupp et al. 2009; Michaelsen et al. 2013). Moreover, the complex biology that 
GBM has is much unknown despite decades of research making GBM difficult to treat, 
so it remains largely incurable (Dunn et al. 2012) that leads to an enormous individual 
and societal burden (Hanif et al. 2017; Dorte et al. 2016; Chen et al. 2018; Arvold et al 
2014).  
Age. GBM is an elderly disease, and it mostly diagnosed at 64 years. It is rare in 
children, and it is reported in children among 0 to 19 years olds, accounting for only 
approximately 3% of all brain and CNS tumors (Chakrabarti et al. 2005). Glioblastoma 
accounts for 50% of glioma in all age groups (Hanif et al. 2017), but the peak incidence 
is in patients between 55 to 60 years old and a median age of 64 years (Xu et al. 2017; 
Schwartzbaum et al. 2006; Ostrom et al. 2013; Ostrom et al. 2014).  In the United States, 
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primary malignant brain tumors are rare and account for about 2% of all adult cancers 
(American Cancer Society 2012), with an incidence for GBM of 3.19 per 100,000 people 
per year, and the age-adjusted GBM rates being 2.5 times higher in European Americans 
than in African Americans (Song et al. 2009). Overall, among brain tumors, GMB is the 
most common and most deadly in adults.  
 
Gender. According to the WHO, the incidence of GBM is dependent on race and 
gender. The incidence in males is 1.6 times higher compared to females (3.97 vs. 2.53)  
(Wen and Kesari 2008; Ostrom et al. 2013). Primary GBM tumors occur most frequently 
in men (male-to-female ratio, 1:33) and secondary GBMs in women (male-to-female 
ratio, 0:65) (Ohgaki et al. 2004; Sturm et al. 2014).  
 
Ethnicity. Patient long-term survival may be affected by Ethnicity. Blacks, 
Asian/Pacific Islanders (API), and American Indian/Alaska Native have a lower GBM 
incidence rate (IR) compare to whites who have the highest IR while Hispanics have 
better survival than non-Hispanics (Thakkar et al. 2014). Whites had 2 times higher IR as 
compared with blacks with lower incidence in Asian-Pacific Islanders, and American 
Indians (Ohgaki and Kleihues 2005; Wrensch et al. 2002; Patel et al. 2019).  
 
1.1.2 Standard Care of Glioblastoma 
Once a patient is diagnosed with GBM, when possible, surgical resection remains 
the first step followed by adjuvant radiotherapy and chemotherapy (Ryu et al. 2014; 
Huang et al. 2017). Since 2005, chemotherapy both during and following radiation 
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therapy is part of the first-line treatment for GBM. Temozolomide, an alkylating 
cytotoxic agent, is administered orally on a daily basis at a dose of 75 mg/m2 throughout 
radiotherapy, usually 60 Gy, 2 Gy in 30 fractions. Four weeks later, magnetic resonance 
imaging (MRI) is repeated and TMZ is then given at a dose of 150-200 mg/m2 daily for 5 
days in 28-day cycles for maintenance. A brain MRI is performed after every 2-3 cycles 
of TMZ treatment (or every 2-3 months) to ensure continued stable disease or response of 
the tumor to treatment (Stupp et al. 2009).  
According to the results of the phase III EORTC 26981, TMZ treatment along 
with radiotherapy resulted in an improved median overall survival (OS) from 12.1 to 14.6 
months, and an increase in the 2-year survival rate from 10% to 27% (Stupp et al. 2005; 
Mirimanoff and Stupp 2007). The cytotoxic activity and apoptosis caused by TMZ and 
other alkylating agents are apparent by the formation of O-6-methylguanine DNA 
adducts, which are repaired by the enzyme O-6-methylguanine-DNA methyltransferase 
(MGMT) (Quinn et al. 2009). Methylation of the MGMT promoter in tumor cells results 
in decreased expression of this enzyme and thus renders tumor cells more susceptible to 
alkylating agents (Hegi et al. 2005). Likewise, the primary mechanism of resistance to 
TMZ is dependent on MGMT activity (Wick 2009). High levels of MGMT activity in 
cancer cells create a resistant phenotype by blunting the therapeutic effect of alkylating 
agents and may be an important determinant of treatment failure (St-Coeur et al. 2015). 
Thus, novel approaches to treat glioblastoma remain a great need, since all current 
therapeutics (whether surgery, chemotherapy and/or radiation) fail to cure GBM. 
However, any new therapy should be specific and controllable and should also be able to 
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cross the BBB to be effective. Peptide-derived vaccines, which are an immunotherapy 
strategy might be the next-generation therapy to treat cancer. 
 
1.2 Immunology of Glioblastoma  
1.2.1. Introduction 
 Cancer immunotherapy has become a promising therapeutic modality to treat 
many tumor types, including GBM, but cancer cells have developed multiples 
mechanisms to evade the effector functions of the immune system and hinder the efficacy 
of effective immunotherapy, eventually. (Gonzalez et al.  2018; Jackson et al. 2019) . In 
GBM, for example, tumor heterogeneity is a hallmark. There are few targets and the 
same targets are not present in all patients. Hence, one drug may not be useful to treat 
most patients (Friedmann-Morvinski 2014). Another aspect to consider is, the blood-
brain barrier (BBB) that poses several challenges for effective drug delivery (Harder et al. 
2018). One challenge is, reaching and maintaining effective CNS permeation and drug 
concentration. CNS tumors, including GBM, compromise the structural integrity of the 
BBB causing more permeability at the tumor core (Chack et al. 2013).  
The suppressive microenvironment in GBM allows immune escape and is 
mediated by many mechanisms (McGranahan et al. 2016; Wieser et al. 2018; Lehtipuro 
et al. 2019; Zhai et al. 2015). These include but are not limited to: 1. secretion of 
immunosuppressive cytokines (Transforming growth factor beta (TGF-β) and Interleukin 
10 (IL-10)), 2. depletion of essential nutrients (by indoleamine dioxygenase (IDO) and 
arginase-1), 3. expression of inhibitory molecules such as Fas ligand (FasL), programmed 
cell death protein (PD-1) and its associated ligand (PD-L1), cluster  differentiation 200 
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(CD200), and 4. recruitment or induction of immunosuppressive cells, such as regulatory 
T cells (Tregs), myeloid-derived suppressor cells (MDSCs) and tumor-associated 
macrophages (TAMs). (Wang et al. 2018; Zhai et al. 2015; Olin et al. 2014). Thus, these 
immunosuppressive mechanisms, in conjunction with its propensity to infiltrate vital 
brain structures, and the regenerative capacity of treatment-resistant cancer stem cells 
(Jackson et al. 2019), make GMB a disease difficult to treat. However, curative 
immunotherapy, therefore, must break GBM immunosuppression and induce immune 
activation. 
 
1.2.2 Immunosuppression Mechanisms of Glioblastoma 
 Systemic immunosuppression is a hallmark in GBM patients, and these 
immunological mechanisms are incompletely defined, but seems to involve both tumor-
intrinsic factors and host response to tumor antigens originating from CNS (Jackson et al. 
2019). Tumor cell-intrinsic factors are mostly related to intertumoral and intratumoral 
heterogeneity (ITH) that shape the archetype of GBM, and these include not only random 
mutations but critical drivers of cell survival and proliferation. Tumor-intrinsic factors 
include downregulation of neoantigens, alterations in IFN-γ signaling, activation of 
WNT–β-catenin pathway, mutations in the PTEN11 gene and loss of heterozygosity of 
loci containing genes encoding human leukocyte antigens (Jackson et al. 2019; Sharma et 
al.  2017; Zhao et al. 2019). Signaling pathways and the expression of immune check 
point molecules like IDO, PD-1, arginase-1, TGF-β, and signal transducer and activator 
of transcription 3 (STAT3) that suppress an immune response, are tumor-extrinsic factors 
or host response involved in GBM-associated immunosuppression (Bloch et al. 2013; 
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Pardoll et al. 2012; Veglia et al.  2018). Thus, for these, intrinsic and extrinsic factors, 
GBM is classified as high intrinsic resistance and high adaptive resistance (Jackson et al 
2019) making GBM a recalcitrant tumor. 
 GBM tumor-intrinsic factors. ITH is the baseline of why GBM exhibits 
transiently potent adaptive and acquired resistance mechanisms. For example, one study 
collected spatially distinct tumor fragments from 11 GB patients and discovered different 
GBM molecular subtypes are within the same tumor (Sottoriva et al. 2013). Moreover, it 
has found intratumor heterogeneity at the copy number level at different stages of cancer 
progression. Some malignant clones exhibited loss alteration in CDKN2A/B and 
amplification of EGFR, CDK6, and MET at early stages, and copy number aberrations in 
genomic regions containing PDGFRA, PTEN, and TP53 occur at the latter stages 
(McLendon et al.  2008; Verhaak et al.  2010; Sottoriva et al. 2013). Furthermore, ITH 
has demonstrated in recurrence of GBM. Another study showed that recurrent and initial 
GBM share around 50% of the mutations, only, suggesting that therapy selects few early-
stage clones or drives bottleneck for tumor evolution at the very early stage (Johnson et 
al.  2014; Kim et al.  2015). Thus, molecular heterogeneity undoubtedly represents an 
important mechanism of intrinsic resistance in GBM (Qazi et al. 2017), hampering the 
efficacy of immunotherapy. 
Extrinsic mechanisms. GBM cells induce T cell tolerance and 
immunosuppression through the expression of the enzyme, IDO, and leading to the 
activation, expansion, and recruitment of Treg (Wainwright et al. 2014).  The role of 
STAT3 in suppressing immune cell activity in GBM has characterized by Ganguly et al.  
2018. For instance, interleukin-2 (IL-2)-mediated STAT3 activity expands tumor-
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associated Tregs enhancing the expression of Forkhead Box P3 protein (Foxp3) in 
CD4+CD25+ T cells (Kortylewski et al. 2005; See et al. 2015). STAT3 expression in 
antigen presenting cells (APC), such as tumor-associated macrophages or microglia, 
results in the suppression of anti-tumor mechanisms and tolerance to tumor antigens. 
STAT3 has been shown to skew effective T helper (Th) 1 responses toward suppressive 
Th17 responses (Kryczek et al. 2007). STAT3 expression is driven by IL-10 which, 
together with TGFβ and prostaglandins, are some of the immunosuppressive mediators 
identified in GBM patients (Ganguly et al.  2018).  
Several studies have shown that immune escape mechanisms involve direct 
interactions between GBM cells and immune cells (Wang et al. 20018). Glioma cells, for 
instance, show high expression levels of non-classical major histocompatibility complex 
(MHC) class I proteins such as human leukocyte antigens (HLA) -E and -G (Friese et al. 
2003; Gupta et al. 2013), which inhibit NK cell-mediated lysis most likely by interacting 
with killer cell immunoglobulin (Ig)-like receptors. (Wischhusen et al. 2005; Wiendl et 
al. 2002). GBM cells also express FasL inducing apoptosis in invading T cells via 
Fas/FasL interactions (Didenko et al. 2002) or triggering inhibitory T cell checkpoints by 
PD-L1 (Parsa et al. 2007; Avril et al. 2010).  
 Myeloid cells, particularly macrophages, are major contributors in GBM-
associated immunosuppression, in addition to immunosuppressive molecules. (Wang et 
al. 20018). It has reported that glioma-associated macrophages express and secrete 
multiple factors including stress-inducible protein 1 (STI1), epidermal growth factor 
(EGF), TGF-β, and membrane-type 1 matrix metalloproteinase (MT1-MMP) to promote 
glioma cell survival, proliferation, and migration (Coniglio et al. 2012; Wesolowska et al. 
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2008). Glioma cells induce macrophage recruitment by releasing chemoattractants like 
the chemokine, C-X-C motif ligand 12 (CXCL12), glial cell-derived neurotrophic factor 
(GDNF), and colony stimulating factor 1 (CSF-1) (Sielska et al. 2013; Wang et al. 2012). 
Unlike other tumors such as melanoma or lung cancer, the paucity of T cells in the GBM 
tumor microenvironment is unique, and resident microglia and macrophages exceed 
infiltrating T cells (Dunn et al. 2007). In brief, GBM is a highly immunosuppressive 
tumor but the exact mechanism of immune escape is unknown. 
   
1.2.3. Checkpoint Inhibitors  
1.2.3.1 Cytotoxic T-lymphocyte Associated Protein 4 Inhibitors 
 CTLA-4 is a member of the B7 family and is constitutively expressed on Tregs 
and transiently upregulated on effector T cells (Brunet et al. 1987). CTLA-4 is a ligand 
for the co-stimulatory molecule CD28 on T cells, which is important for activation and 
proliferation of effector T cells. CTLA-4 binds to CD28 with a higher affinity than CD80 
or CD86, so that CTLA-4 expressing T cells can outcompete CD28-expressing T cells for 
binding to these co-stimulatory molecules on APCs inhibiting T cell activation (Linsley 
et al. 1994; Pardoll et al. 2012).  
 The effectiveness of CTLA-4 inhibition has been proven in preclinical murine 
models of GBM. Mice bearing tumors induced with the murine orthotopic glioma cell 
line, SMA-560, were treated with CTLA-4 antibody and 80% of treated mice exhibited 
benefit in survival compared to 0% in the control group (Fecci et al. 2007). In another 
report, the same survival benefit was observed in mice treated with anti-CTLA-4 therapy 
after being challenged with GL26, a murine glioma cell line (Wainwright et al. 2014).  
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 In humans, anti-CTLA-4 therapy, commercially known as ipilimumab, has been 
used to treat metastatic melanoma. In a cohort of melanoma patients, ipilimumab 
demonstrated a statistically significant 2.1month improvement in overall survival 
(Callahan 2010), and the majority of patients were alive after 2 years of being treated 
(Robert et al. 2011). Moreover, the benefit of survival was similar in both patients with 
brain metastases and patients without brain metastases, supporting the hypothesis of 
immunotherapy activity against CNS malignancies (Margoli et al. 2012). However, the 
use of  CTLA-4 antibody has failed as a monotherapy to treat other cancer types (Chae et 
al. 2018) including CNS tumors and has been replaced by PD-1/PD-L1 therapy, or in 
with CTLA-4 which has demonstrated enhanced and broader clinical efficacy in various 
types of tumors, including GBM (Spencer et al. 2019). Hence, the combination of PD-1 
and CTLA-4 monoclonal antibodies has been successful in increasing the response rates 
and median survival time in multiples cancer types and in cancer patients.  
 
1.2.3.2 Programmed Cell Death Protein 1 and Programmed Death-Ligand Axis (PD-
1/PD-L1 Axis) 
 PD-1 is expressed on activated T cells, B cells, and NK cells. (Ishida, et al. 1992), 
including tumor-specific T cells (Gros et al. 2014) and Tregs (Loise et al. 2009). Normal 
tissue expresses PD-L1 and, similar to CTLA-4, plays an important role in maintaining 
peripheral tolerance. PD-L1 is involved in controlling host immune responses and its 
expression is induced through exposure to IFN-! (Han et al. 2009). Also, PD-L1 is 
expressed on immunosuppressive immune cells including macrophages, MDSCs, and 
Tregs, suggesting that PD-1/PD-L1 axis might be another mechanism of suppression in 
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tumor-infiltrating leukocytes (Pardoll 2012). The exact mechanism of how the PD-1/PD-
L1 axis induces tumor immunosuppression is not entirely understood and might be 
multifactorial.  
PD1 signaling has different outcomes anergic state, for example, results in the 
engagement of PD-1 on activated T cells, which makes them unable to proliferate or 
produce effector molecules upon engagement of the TCR cognate antigen.  (Barber et al. 
2006). On the other hand, the expression of PDL-1 by tumor cells results in resistance to 
the elimination of cancer cells by tumor-specific T cells (Dong et al. 2002). Additionally, 
an increased number of glioma cells expressing PD-L1 and higher levels of PD-L1 
expression have been positively correlated with higher-grade gliomas (Garber et al. 
2016). 
In preclinical mouse models, disruption of the PD-1/PD-L1 pathway through the 
use of inhibitory monoclonal antibodies resulted in enhanced efficacy, suggesting that it 
might be a more dominant mechanism of immune evasion. For example, several studies 
showed improved overall survival with anti-PD1 or anti-PD-L1 antibodies compared to 
anti-CTLA-4 in mice with intracranially implanted GL261 (Wainwright et al. 2014; Zeng 
et al. 2013). Furthermore, several clinical studies have shown that the combination 
therapy of the PD-1/ PD-L1, and CTLA-4 blockade is superior to either monotherapy, 
suggesting a nonredundant role of these immune checkpoint pathways in immune 
evasion.  
Clinically, similar results have shown in preclinical models that combination 
immunotherapy, a treatment modality that combines two or more therapeutic agents, is a 
cornerstone of cancer therapy (Callahan et al. 2016; Bayat et al. 2017). A study showed 
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that TIM-3, which is an alternative immune checkpoint, in combination with PD1 
improved survival in a preclinical model, synergistically (Kim et al. 2017). The dual 
therapy TGIT- and PD1-blocking antibodies synergistically improved survival in a 
preclinical model, compared to control and monotherapy groups. Moreover, the 
combination therapy increased effector T cell function and downregulation of suppressive 
Tregs and tumor-infiltrating dendritic cells (TIDCs) (Hung et al. 2018). Combination 
immunotherapy with anti-PD-1 and anti-CXCR4 in a murine glioma model significantly 
increased survival and improved CD4+/CD8+ ratios in the brain, contributing to 
increased levels of pro-inflammatory cytokines (Wu et al. 2019). Thus, combination 
therapy is effective in increasing the response and survival rates in preclinical mouse 
glioma models. 
 
1.2.3.3 Toxicity Associated with Immune Checkpoint Therapy 
 Immunotherapy may be a new avenue to improve GBM treatment given its 
success in mouse glioma models and other tumor types. However, the increased use of 
immune-based therapies results in immune-related adverse events (irAEs). These 
immune-related adverse events result from non-specific activation of the immune system 
and can affect almost any organ (Eggermont et al. 2016). The incidence of any grade of 
irAEs has been reported to be as high as 90% with single-agent immune checkpoint 
inhibitor (ICI) therapy (Bertrand et al. 2015), but a meta-analysis of the genitourinary 
(GU) malignancies indicates an overall incidence of <75% with anti-CTLA-4 
monotherapy (ipilimumab) and ≤30% in phase 3 trials of anti-PD-1/PD-L1 agents 
(Maughan et al. 2017; Topalian et al. 2012). IrAEs ≥ grade 3 severity occurred in up to 
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43% of patients taking ipilimumab and 20% taking PD-1/PD-L1 agents (Kumar et al. 
2017). The incidence of irAEs is dose-dependent with ipilimumab and pembrolizumab, 
an anti-PD-1 antibody, showing greater toxicity at higher dose levels. Hence, toxicity 
also varies in the adjuvant and metastatic disease settings (Ascierto et al. 2017; Collins et 
al. 2017). 
 Dermatologic adverse effects more frequently related to the use of ICIs are 
maculopapular rash and pruritus, but lichenoid, eczematous, and bullous dermatitis, and 
psoriasis have also been reported. Dermatologic toxicity (all grades) was reported in 30–
40% of patients taking PD-1/PD-L1 inhibitors and approximately 50% of patients treated 
with anti-CTLA-4 antibody, ipilimumab. Belum (Belum et al. 2016) reported that 13–
20% of patients taking anti-PD-1 antibodies, pembrolizumab or nivolumab, developed 
rash or pruritus (all-grade) and approximately 8% of patients with melanoma developed 
vitiligo. Recently, hair re-pigmentation has also been described in patients treated with 
anti-PD-1 or anti-PD-L1 therapy (Rivera et al. 2017). Hence, ICI induces dermatologic 
affecting mainly skin. 
 Gastrointestinal adverse effects, such as diarrhea, are the most frequently reported 
irAEs in patients taking ICIs. The incidence of irAEs is higher (44%) in patients taking 
combination anti-CTLA-4/anti-PD-1 therapy than those receiving anti-CTLA-4 (23–
33%) or anti-PD-1 (≤19%) monotherapy (Larkin et al. 2015). Another commonly 
reported irAE is hepatitis although it is less frequently observed. In patients treated with 
anti-PD-1 ICI, the incidence of hepatitis is approximately 5%, but in patients treated with 
combination ipilimumab and nivolumab this rises to 30% (Spain et al. 2016). 
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 Pulmonary adverse effects, such as pneumonitis, are the most common lung 
toxicity observed in patients receiving ICI treatment. With monotherapy, the overall 
incidence of pneumonitis related to PD-1/PDL-1 and CTLA-4-targeted therapies was 
<5% and high-grade (≥ grade 3) irAEs occurring in 1–2% of patients. However, the 
incidence of pneumonitis with Combinations of PD-1 and CTLA-4 inhibitors was higher 
versus monotherapy (19 of 199 [10%] v 24 of 716 [3%]; P < .01) (Naidoo et al. 2017). 
 Infusion reactions are symptoms such as fever, rigor, pruritus, hypotension, 
dyspnea, chest discomfort, rash, urticaria, angioedema, wheezing or tachycardia that 
occur while the inhibitors are being administered.  Infusion reactions were reported in 
25% of patients receiving avelumab so premedication with acetaminophen and an 
antihistamine is recommended and in < 10% of patients receiving other approved 
immune checkpoints inhibitors (Genentech 2017). 
 
1.3 Targeting the CD200 Immune Checkpoint 
1.3.1 Introduction 
CD200 is an immunosuppressive protein that belongs to the immunoglobulin 
superfamily. The CD200 protein is a widely expressed cell surface protein in a variety of 
tissues and cells including B cells, T cells, kidney cells, placenta cells, neurons and others 
(Wright et al. 2003). CD200 consists of extracellular, transmembrane, and intracellular 
domains. The intracellular region of CD200 protein lacks a signaling motif, therefore 
signaling by CD200 must be transduced via its receptors (Wright et al. 2000; Wright et 
al. 2003). In contrast, the CD200 receptor (CD200R) whose expression is more restricted 
to cells of the myeloid and lymphoid lineage has a long intracellular region with a 
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signaling motif that transmits signals affecting responses in multiple physiological 
systems. Thus, CD200/CD200R axis expression exerts effects on cancer growth, 
autoimmune and allergic disorders, infection, transplantation, bone development and 
homeostasis, and reproductive biology through the intracytoplasmic signaling motif of 
CD200R. 
Several related genes coding for CD200 receptors in addition to that for CD200R 
have been identified. These genes have been called the activation receptors of CD200 
protein because the encoding proteins lack cytoplasmic domains able to recruit signaling 
molecules directly and are thought to function by coopting accessory molecules 
(DAP10/12) for their function (Wright et al. 2003; Voehringer et al. 2004). However, 
whether these gene products also regulate immune function is controversial. Hence, 
understanding how the CD200 protein and its receptors modulate the immune system has 
implications in the development of new therapeutic approaches. 
 
1.3.2 Distribution and Identification of CD200 Protein and Its Receptor CD200R 
In 1982, the CD200 protein was initially discovered in rats and it was called OX2. 
It was characterized as a 41- to 47-kDa cell surface glycoprotein. In 2000, the OX2 
protein was designated CD200 and will be referred to by this terminology for the 
remainder of this thesis. It is expressed on a variety of cell types, including thymocytes, B 
cells, activated T cells, follicular dendritic cells, endothelium (McMaster 1979), neurons 
in the central nervous system (including retina and optic nerve) (Webb 1984, Dick et al. 
2001), cells of reproductive organs (Bukovský et al. 1984), and kidney glomeruli (Wright 
et al. 2001). It is thought the CD200 protein has a particular and important biological 
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function because of its conserved, unusual and specific, rather than ubiquitous, 
distribution. Sequence analysis revealed it belonged to the immunoglobulin superfamily 
(IgSF) and contained two IgSF domains, a single transmembrane domain and a short 
cytoplasmic domain. Evolutionary studies showed that CD200 distribution was relatively 
conserved across species consistent with the molecule having an important biological 
function (Barclay and Ward 1982).  
 Separately, two groups used recombinant DNA technology to identify a molecule 
(OX2R or CD200R) recognized by an antibody that blocked CD200 binding to 
macrophages. CD200R was purified from rat spleen cells and identified as a novel 
protein, similar in structure to CD200 that contained two IgSF domains, but with a larger 
cytoplasmic domain thereby having potential signaling capacity (Wright et al. 2000). 
Phenotypic analysis revealed the receptor was expressed by cells of myeloid lineage. 
Hence, the CD200/CD200R axis distribution has similarities with the CD47-CD172a 
Signal regulatory protein alpha (SIRP-α) interaction in that CD47 is widely distributed 
and its receptor, CD172a, is mostly expressed by myeloid cells. Signaling via CD172a 
has been shown to downregulate myeloid cells through tyrosine phosphatases, Src 
homology 2 domain-containing protein tyrosine phosphatase 1(SHP1) and Src homology 
region 2-containing protein tyrosine phosphatase 2 (SHP2) (Kharitonenkov et al. 1994). 
Basic studies into the role of the CD200 protein in biological systems have raised 
tantalizing possibilities about the function of CD200 in the immune system. One 
hypothesis is that the CD200 protein is a costimulatory molecule, which is supported by 
the following facts, first, the gene-encoding for the CD200 protein and the costimulatory 
molecules, CD80 and CD86, are closely linked on chromosome 3 in mouse model 
 16 
(Borriello et al. 1998), 2) CD80 and CD86 on APC are the ligands for the activating 
receptor CD28 and inhibitory receptor CD152 which are expressed on T cells (Linsley et 
al. 1993; Beyersdorf et al. 2015), 3)  CD80 and CD86 are structurally related to OX2, 
each having one IgV and one IgC-like domain since these molecules belong to Ig family 
protein (Linsley et al. 1994).T cells stimulation assay using CD200 CHO cell 
transfectants failed to generate IL-2, IL-4 or IFN-γ, and T-cell growth and immune 
activation associated cytokines, leading to the conclusion that co-stimulation was 
incomplete, and this response was independent of the CD28/CD152 pathway (Borriello et 
al. 1998). However, work confirming the role of CD200 as a costimulatory molecule has 
not reported until now.  
The immunosuppressive role of CD200 protein has been demonstrated by several 
studies. Gorczynski reported increased graft survival in an in vivo mouse model of allo- 
and xenograft transplantation due to the expression of CD200 on a subpopulation of 
NLDC145+ dendritic cells. They suggested that the engagement between CD200 and its 
CD200R delivered an immunosuppressive signal to these dendritic cells. Additionally, 
the increased graft survival could be reversed using a monoclonal antibody (mAb) 
specific for mouse CD200 (Gorczynski et al. 1999). Thus, these studies show that the 
natural functions of CD200 protein remain controversial; in some contexts, CD200 exerts 






1.3.3 CD200 Receptor Family 
1.3.3.1 The Inhibitory CD200 Receptor (CD200R) 
 The inhibitory receptor CD200R (from human, mouse rat) was originally 
described by Barclay and colleagues in Oxford, and there is a consensus that CD200 is its 
natural ligand. (Wright et al. 2003; Voehringer et al. 2004; Hatherley et al. 2005). The 
CD200R and CD200 are closely related molecules implying evolution from a common 
ancestral protein (Wright et al. 2000). The human CD200R gene was characterized and 
mapped to chromosome 3q12-13 (Vieites et al. 2003). The human and mouse the tissue 
distribution, chromosomal location, and sequence of CD200R was confirmed by 
Gorczynski and colleagues (Gorczynski et al. 2004). CD200R exhibits a high content of 
N-linked glycosylation sites, 8 in the rat and 10 in the mouse (Preston et al. 1997). In 
addition, the cytoplasmic region of the receptor contained a NPXY motif that can interact 
with a phosphotyrosine-binding (PTB) domain present in several signaling adaptor 
molecules. The binding affinity of the interaction between CD200 and CD200R is 
comparatively low (KD = 2.5 μM) typical of interactions between migratory cells (Van 
der Merwe et al. 1993).  
 Unlike other well described myeloid inhibitory immune receptors such as 
FcεRIIB, GP49B1, or paired Ig-like receptors (PIRs), CD200R does not contain an 
immunotyrosine-based inhibitory motif (ITIM) (Ravetch and Lanier 2000). Tyrosine 
phosphorylation occurring following CD200:CD200R interactions depends upon the 
NPXY motif, leading to phosphorylation of docking protein 1(Dok1) and docking protein 
1(Dok2) proteins, binding of Rasfamily GTPase-activating proteins (Ras-GAP) and Src 
homology 2 domain-containing protein tyrosine phosphatase (SHIP), and subsequent 
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downstream inhibition of the Ras-MAPK pathways (Zhang et al. 2004). Mihrshahi and 
Brown (2010) reported that following CD200:CD200R interaction, the phosphorylation 
of Dok2 preceded phosphorylation of Dok1 and recruitment of different downstream 
proteins by Dok2 and Dok1. Dok1 recruited considerably less RasGAP than Dok2, which 
also recruited the adaptor molecule non-catalytic region of tyrosine kinase adaptor 
protein 1 (Nck). In contrast, phosphorylation of Dok1 led to recruitment of CrkL. Using 
knockdown of Dok1 and Crk-like protein (CrkL) expression in U937 cells, a human 
histiocytic lymphoma cells, they showed increased Dok2 phosphorylation and Ras-GAP 
recruitment to Dok2. The authors suggest a model in which Dok1 negatively regulates 
Dok2-mediated CD200R signaling through recruitment of CrkL (Mihrshahi and Brown 
2010).  
 A series of 15-mer synthetic peptides designed on the CD200 sequence were 
characterized at the functional level. The ability of these molecules to block binding of 
CD200R to CD200 was studied using competitive ELISA and CD200Fc fusion protein. 
Results were also duplicated in a FACS-based assay using CD200Fc fusion protein and 
infusion of these peptides abrogated the protective effects of CD200Fc fusion proteins in 
a mouse allograft model indicating in vivo activity. The mechanisms of these peptides 
exert their effects needs to further be elucidated (Chen et al. 2005; Gorczynski et al. 
2001). 
 
1.3.3.2 CD200R Family Gene Products  
At least four murine CD200R-related genes, termed mCD200RLa-c by Wright in 
2003 but referred to here as CD200AR2, -AR3, -AR4, -AR5, and a single related human 
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gene designated hCD200RLa have been characterized (Wright et al. 2003). CD200La and 
Lb (CD200AR4 and CD200AR3) isoforms were characterized and showed close 
sequence homology to CD200R in the extracellular regions with short cytoplasmic 
regions containing a positively charged lysine residue in the transmembrane region. 
Immunoprecipitation confirmed that this lysine residue would form a salt bridge with 
DAP12 and enable signal transduction.  The transmembrane region of hCD200RLa was 
also found to have a positively charged amino acid (Voehringer et al. 2004).  
Wright GJ, et al. in 2003 reported the gene expression and tissue distribution of 
the CD200AR4 and AR3 using RT-PCR. The highest level of mCD200AR4 was 
observed in resting mast cells, but the activation via FcεR1 decreased. Furthermore, 
lower expression on Th2 cells was observed. In contrast, mCD200AR3 was primarily 
expressed in activated mast cells, polarized Th2 cells, and to a lesser degree in cultured 
DC, but was virtually undetectable in cultured macrophages. (Wright et al. 2003) These 
genes may have specific, rather than redundant functions in the murine immune response 
based on their differential gene expression (Wright et al. 2003; Hatherley et al. 2005). In 
contrast, the human CD200RLa amino acid analysis showed that it lacked two cysteine 
residues critical for expression. Today, these key points are assumed: 1) no CD200RL 
molecules bind CD200; 2) the human CD200RLa has not been expressed as a functional 
protein; 3) it is likely that these are activating receptors, and 4) the ligands and signaling 
pathways have not been identified. 
The nomenclature in mice of the CD200 activation receptors was updated based 
on sequencing analysis by Gorczynski and colleagues in 2004. These were termed 
CD200AR2 (corresponding to CD200RLc), CD200AR3 (corresponding to CD200Lb), 
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and CD200AR4 (corresponding to CD200La). Comparison of sequence data from Wright 
in 2003 indicated NH2-terminal differences for CD200AR2 and AR3 compared with 
CD200RLc and CD200RLb. Charged residues in the cytoplasmic domains of CD200R2-
4 were found, but whether they were associated with ITAM was not determined. Using 
flow cytometry, COS7 cells transfected with all CD200R isoforms appeared to bind 
FITC-labelled CD200Fc contradicting previous reports that only the inhibitory CD200R 
bound CD200. However, these experiments were conducted in the absence of DAP12 
expression by the transfected cells and it is probable that positive binding observed in 
these studies was an artifact. Moreover, the co-expression of DAP-12 has been confirmed 
independently for CD200R3 (CD200RLb) (Voehringer et.al. 2004). These findings 
suggest that the CD200 receptor family resembles other gene/protein families such as the 
SIRPs, Ly49 natural killer cell, Ig-like receptors and PILR, which have both activating 
and inhibiting forms (Barclay et al. 2002; Long 1999; Seiffert et al. 2001).  
Thus far, it has been shown that CD200 binds to the inhibitory CD200R. In 2005, 
Hatherley et al. demonstrated using flow cytometry that only cells expressing CD200R 
bound a CD200-Fc fusion protein. Using surface plasmon resonance, an optical technique 
that is utilized to measure of the receptor/ligand interaction was confirmed at the protein 
level that CD200R binds to CD200-Fc fusion protein. The affinity of CD200R binding 
was calculated as Kd ∼ 4 μM. Binding of CD200AR4 was too weak to measure 
accurately and no binding of CD200AR3, CD200AR2, or CD200AR5 could be detected 
using this sensitive assay (Hatherley et al. 2005). Sequence analysis between CD200 and 
its receptors revealed that strain-specific gene CD200RLe appears to be the most closely 
related (91%) to CD200R compared with CD200AR2 (83%), CD200AR3 (39%), and 
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CD200AR4 (84%). Mutagenesis analysis showed that single residue change in the 
predicted β strands C and F of the human CD200 protein was sufficient to prevent 
binding (Hatherley and Barclay 2004). These findings are very important for potential 
therapies targeting the CD200/CD200R axis because it suggests that immune response 
can be modulated for the development of new cancer immunotherapy approaches. 
 
1.3.4 The role of CD200 Protein in Immunosuppression 
 It has been shown that the CD200/CD200R axis has a role in maintaining 
immunological non-responsiveness in myeloid APCs (Taylor et al. 2005). However, 
CD200−/− mice do not develop spontaneous autoimmune disease implying that central 
tolerance is not compromised. Nevertheless, the role of the CD200 protein in reinforcing 
peripheral tolerance has not been tested. Rosenblum and colleagues (2004) discovered a 
novel mechanism where upregulation of CD200 reinforces suppression of immune 
reactivity to self-antigens under steady state conditions (Rosenblum et al. 2004). They 
concluded this because CD200 protein was increased on dendritic cells undergoing 
apoptosis in vivo as well as in vitro. Another mechanism by which CD200 protein 
reinforces peripheral tolerance may involve tryptophan metabolism by the enzyme, 
indoleamine 2,3-dioxygenase.  
The ligation of CD200R using a CD200-Ig fusion protein induced IDO expression 
and function mimicking the effects of B7/CTLA4 signaling in plasmacytoid dendritic 
cells. These findings led to the hypothesis that the CD200/CD200R axis acts to reinforce 
the tolerogenic properties of certain DC subsets over the adjuvant activity of 
immunogenic subsets (Fallarino et al. 2004). This was then proved by showing that 
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CD200R-Ig signaling upregulated IDO via type-1 IFN induction, whereas CTLA-4-Ig 
induced IDO induction was IFN-γ-dependent, suggesting an additional or alternative 
route to IDO expression and regulation (Fallarino et al. 2004; Fallarino et al 2005) 
 
1.3.5 The Significance of CD200:CD200R Axis in the Immune Response to Tumors 
In 2001, infusion of soluble CD200Fc was used to attenuate tumor growth of 
murine transplantable thymoma (EL4) in C57BL/6 mice. This was the first indication that 
the CD200/CD200R axis may be relevant to cancer biology and, specifically, tumor 
immunity. Since 2001, several groups have reported upregulation and expression of 
CD200 protein in tumors. The CD200 protein is overexpressed in several cancer cell lines 
and/or tissues, including ovarian, melanoma, head and neck carcinoma, testicular, 
malignant mesothelioma, neuroblastoma, renal cell carcinoma, chronic lymphocytic 
leukemia, prostate, and breast and colon cancers (Siva et al. 2007; Kawasaki et al. 2007).  
Fascinatingly, CD200 is implicated as a prognostic factor for several tumor types 
like multiple myeloma (MM), acute myeloid leukemia (AML), and brain tumors 
(Tiribelli et al. 2017; Falay et al. 2018). In MM and AML, CD200 was expressed in 78% 
and 43% of the patients, respectively, and a significant correlation was found between the 
levels of CD200 expression and overall survival (Moreaux et al. 2006; Tonks et al. 2007). 
For brain tumors, GBM cells expressed higher levels of CD200 compared to other types 
of brain tumors and high levels of soluble CD200 (sCD200) in serum were associated 
with poor prognosis (Moertel et al. 2014).  
In human breast cancer, levels of sCD200 in patient serum samples correlated 
with aggressive disease and metastasis. Furthermore, increased levels of sCD200 in 
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chronic lymphocytic leukemia (CLL) patients were reported and these levels correlated 
with the aggressiveness of the disease (Wong et al. 2012). Moreover, CD200 is 
associated with cancer progression (i.e. metastasis or relapse) in cancers of the bladder, 
lung, breast, and prostate, as well as, melanoma and chronic myeloid leukemia (CML) 
(Moreaux et al. 2008). 
These findings indicate that monitoring sCD200 as a biomarker may provide 
significant diagnostic and prognostic information in different cancers and that therapies 














Tumor-derived Vaccines Containing CD200 Inhibit Immune activation: 





There are over 400 ongoing clinical trials using tumor-derived vaccines. This approach is 
especially attractive for many types of brain tumors, including glioblastoma, yet so far, 
the clinical response is highly variable. One contributor to poor response is CD200, 
which acts as a checkpoint blockade, inducing immune tolerance. We demonstrate that, 
in response to vaccination, glioma-derived CD200 suppresses the anti-tumor immune 
response. In contrast, a CD200 peptide inhibitor that activates antigen -presenting cells 
overcomes immune tolerance. The addition of the CD200 inhibitor significantly 
increased leukocyte infiltration into the vaccine site, cytokine and chemokine production, 
and cytolytic activity. Our data therefore suggest that CD200 suppresses the immune 





  Despite over four decades of intense research into vaccine-based strategies for 
fighting cancer, the majority of immunotherapies against solid tumors still fail to achieve 
beneficial outcomes. This is especially true for the central nervous system (CNS) tumor 
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glioblastoma multiforme (GBM). A recent search on ClinicalTrials.gov revealed over 400 
open clinical trials using tumor cells as a source of antigens to stimulate an anti-tumor 
response; twenty-five of these are directed towards CNS tumors.  
The use of tumors as a source of tumor-associated antigens clearly has advantages 
(Olin et al. 2014); however, most cancers have robust mechanisms for evading the 
immune system (Olin et al. 2014). Immune checkpoint inhibitory ligands and their 
receptors tightly control T-cell activation, maintaining self-tolerance and limiting 
immune-mediated collateral tissue damage. Checkpoint blockades such as Cytotoxic T 
lymphocyte antigen-4 (CTLA-4) and programmed death-1 protein (PD-1) (Fife et al. 
2008) have been targeted in multiple clinical trials, demonstrating some success (Olin et 
al. 2014) (Wang et al. 2015). We have extensively studied another checkpoint blockade 
(CD200/CD200R) responsible for shutting down the immune system (Moertel et al. 
2014; Ramsay et al. 2014) making the CD200 blockade interaction an important target 
for cancer immunotherapy (Moreaux et al. 2008; Gorczynski et al. 2008; Kretz-Rommel 
et al. 2008).  
    CD200 has been well characterized as an immunosuppressive protein that inhibits 
immune responses through its receptor (Liao et al. 2013; Gorczynski et al. 2013; Kretz-
Rommel et al. 2007). In healthy individuals, CD200 is distributed on a wide variety of 
tissues, including B-cells, activated T-cells, certain vascular endothelia, kidney, placenta 
cells, and neurons (Wright et al. 2001). In contrast to the distribution of CD200 ligand, its 
receptor, CD200 receptor (CD200R), is mainly expressed on myeloid cells (monocytes, 
granulocytes, dendritic cells). CD200R is also expressed on T-cells and B-cells, 
inactivating leukocytes through negative immune signals (Wright et al. 2003; Rijkers et 
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al. 2008; Hoek et al. 2000). High expression of CD200R has also been detected on 
differentiated central and effector memory T-cells. CD200R expression is particularly 
apparent in polarized Th2 cells (Caserta et al. 2012), resulting in the expansion of 
regulatory T-cells (Gorczynski et al. 2005; Curiel et al. 2004; Jenmalm et al. 2016).  
    CD200 is expressed on tumors such as chronic lymphocytic leukemia (Kretz-
Rommel et al. 2007)  multiple myeloma (Moreaux et al. 2008), acute myeloid leukemia 
(Tonks et al. 2007), melanoma (Petermann et al. 2007), ovarian cancer (Siva et al. 2008), 
metastatic small cell carcinoma (Stumpfova et al. 2010), glioblastoma multiforme (GBM) 
(Moertel et al. 2014) and on the murine glioma GL261 (Figure 1A). In addition, tumor 
progression and poor patient outcome have been shown to correlate with the presence of 
soluble CD200 (Wong et al. 2012). Wong, et al.  reported that soluble CD200 levels in 
the plasma of chronic lymphocytic leukemia patients correlate with tumor burden and 
disease state. In our phase I vaccine trial, we demonstrated increasing levels of CD200 in 
the serum of our GBM and ependymoma immunotherapy patients upon tumor recurrence 
(Moertel et al. 2014). 
 
2.3 Results 
2.3.1 Absorbing CD200 out of Tumor-derived Vaccines Enhances Immunogenicity 
Because CD200 is expressed on tumors, we hypothesized that we are suppressing 
the immune system with the tumor-derived vaccines designed specifically to induce an 
anti-tumor immune response. To test our hypothesis, we depleted CD200 from our tumor 
lysates using immunoprecipitation (Figures 1B&C). OT-I splenocytes were pulsed with 
ovalbumin (OVA) + GL261 tumor lysate (GL261) or GL261 depleted of CD200 (GL261 
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(CD200neg)). GL261 significantly suppressed the ability of OVA to induce an immune 
response (p = 0.009), which was reverted by depleting CD200 from the vaccine (p = 
0.003) (Figure 1D). Because CD200 acts on antigen-presenting cells (Jenmalm MC, et al. 
(2006), we repeated this experiment with bone marrow derived dendritic cells (DC). Our 
experiments recapitulated the findings in Figure 1D that, compared to OVA alone, tumor 
lysates containing CD200 inhibited IFN-γ (p = 0.001) and IL-2 (p = 0.005) production, a 
result which was reversed by depleting CD200 (p = 0.001) (IFN-γ) p = 0.0 (Figure1E) 
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Figure 1. Absorbing CD200 out of Tumor-derived Vaccines Enhances Immunogenicity. (A) 
Human and mouse gliomas were analyzed by western analysis for CD200. (B&C) CD200 was 
absorbed out of murine GL261 tumor lysates and used to pulse (D) OT-1 splenocytes and (E) bone 
marrow derived dendritic cells with OVA as an immune stimulant with either wildtype GL261 or 
GL261 (CD200neg) tumor lysates. Error bars are ± SEM, asterisk represent a statistical significance * 
p<0.05, ** p=0.005 or *** p=0.0005 determined by unpaired t-test. Experiments are representative of 
three separate experiments. 
 
2.3.2 CD200 Inhibitor Blocks Immune Suppression from Tumor-derived Vaccines 
    Targeting receptor-ligand interactions has become increasingly important, as 
indicated by CD200/CD200 receptor (CD200R) in leukemia cells and CD47/SIRP in 
many cancer cells (Akkaya et al. 2013; Gorczynski et al. 2005; Willingham et al. 2007). 
We developed a peptide inhibitor targeting the CD200R isoform activation receptors 
(Moertel et al. 2014). Purified CD11b cells from wildtype mice were pulsed with tumor 
lysate containing CD200, with or without the CD200 inhibitor. In these experiments, with 
the exception of TNF-α and IL1(p = 0.07 and p = 0.12 respectively), tumor lysates alone 
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(IL6), p = 0.02 (CXCL9) and p = 0.006 (RANTES)) compared to no pulse controls. The 
CD200 inhibitor treatment group achieved a statistically significant enhanced immune 
response p = 0.004 ((TNF-α, p = 0.001 (GM-CSF), p = 0.033 (IL1b, p = 0.015 (CXCL9), 
p = 0.001 (IL6) and p = 0.013 (RANTES)) compared to no pulse control and (p = 0.015 
(GM-CSF), p = 0.023  (IL1-α, p = 0.015 (CXCL9), p = 0.015 (IL6) and p = 0.046 
(RANTES) compared to tumor lysate groups alone (Figures 2A-F). We observed 
enhanced secretion of TNF-α when adding the CD200 inhibitor to tumor lysates, 
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Figure 2. CD200 Peptide Inhibitor Blocks the Suppressive Properties of CD200. (A-F) CD11b 
isolated from C57BL/6 wildtype mice were pulsed with tumor lysates derived from wildtype Gl261 
cells +/- the CD200 peptide inhibitor. Supernatants were analyzed for chemokine and cytokine 
secretion. Error bars are ± SEM, asterisk represent a statistical significance * p<0.05 or ** p=0.005 
determined by unpaired t-test. Experiments are representative of three separate experiments. 
 
 
2.3.3 CD200 Inhibitor Enhances an Antigen Specific Response 
    To generate a tumor-specific immune response, CD8 T-cells undergo priming by 
dendritic cells, the antigen-presenting cell most efficient at initiating potent CD8+ T-cell 
responses (Steinman et al. 1978; Banchereau et al. 1998). Currently, the efficacy of ex-vivo 
derived dendritic cell immunotherapy is not well established for human cancers (Soruri et 
al. 2005; Figdor et al. 2004; O'Neill et al. 2004; Olin et al. 2014). The limited success of 
these immunotherapies has been attributed to a variety of factors, including the preparation 
and administration of the vaccine, the disease stage of the participants in experimental 
trials, or the heterogeneous nature of most tumors. We suggest the failure to elicit an anti-
tumor response is due to CD200 in tumor-derived vaccines used to activate dendritic cells.  
    To test this, bone marrow-derived dendritic cells (DC) from wildtype mice were 
pulsed with OVA + CD200 with or without the CD200 inhibitor. Following 24hr 
incubation, cells were washed to remove any free inhibitor, then incubated with purified 
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blocked the suppressive effects of CD200, reverting to an antigen-specific OVA immune 
response (Figure 3A). OVA significantly enhanced an IFN-γ response (p = 0.007), which 
was suppressed with the addition of CD200 (p = 0.009). The addition of the CD200 
inhibitor overpowered the suppressive properties of the CD200 protein, significantly 
enhancing an immune response (p = 0.003), as compared to using OVA alone. 
Interestingly, in these experiments, we observed that cells pulsed with CD200 inhibitor + 
OVA, significantly enhanced the immune response (p = 0.001) (Figure 3B) compared to 
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Figure 3. CD200 Inhibitor Enhances an Antigen Specific Response. (A & B) Bone-marrow 
derived dendritic cells from wildtype C57Bl/6 or CD200R KO mice were pulsed with OVA, OVA + 
CD200, OVA + CD200 + CD200 inhibitor or OVA + CD200 + scrambled inhibitor. Following 24hr 
incubation, cells were washed and purified and OT-I CD8 T-cells were added. Following 48hr 
incubation, supernatants were analyzed for IFN-γ production.  Experiments are representative of three 
separate experiments. Error bars are ± SEM, asterisks represent a statistical significance * p<0.05, ** 
p=0.005 or *** p=0.0005 determined by unpaired t-test. 
 
 
2.3.4 CD200 Inhibitor Modifies Gene Expression   
    To test our hypothesis that the CD200 inhibitor activates antigen-presenting cells, 
CD11b cells from wild type splenocytes were pulsed with CD200 protein, CD200 
inhibitor, or a combination of CD200 protein + CD200 inhibitor and analyzed by 
NanoString for 575 immune related genes. All treatment groups were normalized to no 
pulse controls. In these experiments, 194 immune related genes had a +/- 1.5-fold change 
following pulsing with the CD200 inhibitor alone (Figures 4A-C).  
    When we compared all three treatment groups, we observed that ninety-eight 
genes within the CD200 protein group had an opposite response compared to genes 
within the CD200 inhibitor or CD200 protein + CD200 inhibitor treatment groups 
B 
OVA                             -          +          +          +         + 
CD200 Inhibitor           -          -           +          -          + 


















(Figures 5A&B). These experiments demonstrated that the CD200 inhibitor reversed the 
inhibitory signaling induced by the CD200 protein. 
    To determine if the CD200 inhibitor activated functional responses within 
antigen-presenting cells, DCs were pulsed with the CD200 inhibitor alone. These 
experiments revealed that the CD200 inhibitor activated DCs, statistically enhancing the 
production of IL-2, TNFa, IL-1a, IL-6, GM-CSF, and IL-1a (p = 0.01, p = 0.02, p = 
0.04, p = 0.001, p = 0.004, and p=0.02 respectively) (Figure 6A-H). We observed 
enhanced CXCL9 and IL-12 production, however, responses failed to reach statistical 








































































































Figure 4. CD200 Inhibitor Modifies Gene Expression. Purified CD11b cells isolated from wildtype 
C5Bl/6 mice were pulsed with CD200 inhibitor. RNA was isolated and analyzed by NanoString for 



































































































































































































Figure 5. CD200 Inhibitor Reverses CD200 Protein Inhibitory Signals. Purified CD11b cells 
isolated from wildtype C5Bl/6 mice were pulsed with a CD200 protein, CD200 inhibitor or a 
combination of CD200 protein and CD200 inhibitor. RNA was isolated and analyzed by NanoString 




























Figure 6. CD200 Inhibitor Stimulates Dendritic Cells. (A-H) Bone marrow derived dendritic cells 
from wildtype C57Bl/6 mice were pulsed with CD200 inhibitor. Following 48hr incubation, 
supernatants were analyzed for chemokine and cytokine production. Error bars are ± SEM, asterisk 
represent a statistical significance * p<0.05** or p=0.005 determined by unpaired t-test. 
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2.3.5 CD200 Inhibitor Enhances Leukocyte Trafficking into the Vaccine Site 
 
    GM-CSF is often used in vaccines to enhance the infiltration of antigen-
presenting cells into the vaccine site for antigen uptake and presentation (Morse et al. 
2015). We found that the CD200 inhibitor enhanced production of GM-CSF (Figure 6G) 
in vitro. Therefore, in the next set of experiments, non-tumor-bearing wildtype and 
CD200R KO mice were vaccinated with tumor lysates or CD200 inhibitor alone. 
Twenty-four hours later, mice were revaccinated with tumor lysates + CpG-ODN or 
tumor lysates + CpG-ODN + CD200 inhibitor, respectively. In one of the treatment 
groups, mice were vaccinated with the CD200 inhibitor 1hr prior to revaccination with 
tumor lysates + CD200 inhibitor (Figure 7A-C). 
    Six hours following revaccination, skin at the vaccine site was harvested and 
analyzed for leukocyte infiltration. No significant leukocyte infiltration was observed in 
saline vaccinated controls or in CD200R KO mice vaccinated with tumor lysates + 
CD200 inhibitor (data not shown). To quantify our results, vascular leukocytes from eight 
layers of tissue were counted (Figure 7D). These experiments demonstrated enhanced 
leukocyte infiltration into the vaccine site with as little as 1hr pre-vaccination with the 
CD200 inhibitor (p = 0.001; 1hr and p = 0.001 24hrs) (Figure 7D). Moreover, knocking 
out the CD200 receptor failed to enhance leukocyte infiltration (p = 0.087).  
    These experiments demonstrated that while we were capable of eliciting an 
immune response using tumor-derived vaccines, the response failed to recruit antigen-
presenting cells to the site of vaccination for antigen uptake. We next wanted to see how 
removing CD200 from tumor lysate vaccines influenced leukocyte infiltration. In these 
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experiments, non-tumor-bearing wildtype mice were vaccinated with tumor lysate or 
tumor lysate void of CD200. Twenty-four hours later, mice were revaccinated with tumor 
lysate + CpG-ODN or tumor lysate void of CD200 + CpG-ODN respectively (Figure 
7E). As seen in the above experiments, we observed a significant infiltration of 
leukocytes into the site of vaccination (p = 0.004), however, removal of CD200 















   A. Tumor Lysate                  
B. Tumor Lysate + 
CD200 Inhibitor (1hr)  
C. Tumor Lysate + 




















       Tumor Lysate       +               +                 +                  + 





   1hr 
   24hrs 
 Wildtype mice                  












Figure 7. CD200 Inhibitor Enhances Leukocyte Trafficking into the Vaccine Site. Non-tumor 
bearing C57Bl/6 or CD200R knockout mice were vaccinated with tumor lysates or CD200 inhibitor, 
either 1hr or 24 hrs later, mice were revaccinated with (A) tumor lysates + CpG or (B) tumor lysates, 
CD200 inhibitor + CpG. (1hr revaccination) (C) tumor lysates, CD200 inhibitor + CpG. (24hrs 
revaccination). Six hours later, skin from the vaccine sites was harvested and analyzed by H&E 
staining. (D) Leukocytes within blood vessels in 8 separate skin levels were counted. (E) In separate 
experiments, mice were vaccinated with wildtype GL261 lysates or GL261 lysates void of CD200. 
Twenty-four hours later, mice were revaccinated with either wildtype GL261 lysates or GL261 lysates 
void of CD200 + CpG. Six hours later, skin was harvested and leukocytes within blood vessels in 8 
separate skin levels were counted. Error bars are ± SEM, asterisks represent a statistical significance * 
p<0.05, ** p=0.005 and *** p=0.0005 determined by unpaired t-test. 
 
 
2.3.6 CD200 Inhibitor Enhances an Anti-tumor Response 
    In the next set of experiments, we investigated the effects of CD200 inhibitor on 
the expression of co-stimulatory molecules. In these experiments, we used the OVA 
protein due to the SIINFEKL antigen’s ability to stimulate an immune response. Purified 
CD11b cells isolated from wildtype mice were pulsed with OVA or OVA + CD200 
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CD86, and MHC-II expression (p = 0.012, p = 0.028, and p = 0.038, respectively) as 
compared to no pulse controls (Figure 8A). CD200 inhibitor significantly enhanced the 
expression of CD80 and CD86 (p = 0.032 and 0.018, respectively) compared to the OVA 
alone treatment group.  
    To determine whether the use of our CD200 inhibitor would enhance functional 
responses, we used an in-vivo cytolytic model to investigate the effect of CD200 inhibitor 
on an anti-tumor response. In these experiments, wildtype or CD200R KO mice 
underwent intracranial inoculation as described by Olin et al. (Olin, et al. 2010). Mice 
were vaccinated with tumor lysates with or without the CD200 inhibitor (Figure 8B). 
Scrambled inhibitor was used as a control. Twenty days post-inoculation, lymphocytes 
from draining cervical lymph nodes were harvested and incubated with GL261 cells to 
initiate a tumoricidal response. Two-way ANOVA revealed a statistically significant 
enhancement of an anti-tumor response by lymphocytes with the addition of the CD200 
inhibitor (p = 0.001) (Figure 8B).  
    Individual analysis by Student’s T-test revealed that tumor lysates in both 
wildtype and CD200R knockout mice with significantly enhanced anti-tumor responses 
(p = 0.001 and p = 0.001) at effector:target cell ratios of 25:1 and 50:1, respectively, as 
compared to the saline treatment group. In addition, the CD200 inhibitor group 
significantly enhanced anti-tumor responses (p = 0.001, p = 0.001, and p = 0.001) at 
effector:target cell ratios of 5:1, 25:1, and 50:1, respectively, as compared to the saline 
treatment group. In wild type mice, the CD200 inhibitor treatment group exhibited 
significantly enhanced anti-tumor responses at effector:target cell ratios of 5:1, 25:1, and 
50:1 (p = 0.0001, p = 0.026, and p = 0.003, respectively) as compared to the tumor lysate 
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treatment group. In addition, there were significantly enhanced anti-tumor responses 
between CD200 inhibitor and CD200 scrambled inhibitor control treatment groups in 
wildtype mice at effector:target cell ratios of  5:1, 25:1, and 50:1 (p = 0.001, p = 0.0066, 
and p = 0.0018, respectively). We also observed significantly enhanced anti-tumor 
responses at effector:target cell ratios 5:1, 25:1, and 50:1 (p = 0.006, p = 0.016, and p = 
0.006, respectively) between wildtype and CD200R KO mice in the CD200 inhibitor 
treatment group. No significant differences were observed between wildtype and 
CD200R KO mice treated with tumor lysates or the scrambled inhibitor. These 
experiments demonstrated the ability of our inhibitor to attract leukocytes to the site of 
vaccination. This is important, researchers have often used GM-CSF with their vaccines 
to attract antigen-presenting cells the take up tumor specific antigens for presentation in 


















Figure 8. CD200 Inhibitor Enhances an Anti-tumor Response. (A) Purified CD11b cells from 
wildtype C57Bl/6 cells were pulsed with OVA +/- CD200 inhibitor. Forty-eight hours later, cells were 
analyzed for CD80/86 and MHC-II expression. (B) Tumor-bearing wildtype (solid symbols) or 
CD200 receptor knockout (CD200R KO) (open symbols) mice were vaccinated in the back of the 
neck with saline (black lines), wildtype GL261 tumor lysates (red lines), tumor lysates + scrambled 
CD200 inhibitor (blue lines) or tumor lysate + CD200 inhibitor (green lines).  Twenty days post 
vaccination; lymphocytes from cervical lymph nodes were harvested, incubated for 6 hours with 
wildtype GL261 cells and analyzed for cytolytic activity.  Asterisks represent statistical significance * 
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2.3.7 CD200 is Upregulated on Endothelial Cells  
    Inhibiting CD200/CD200R interactions has been suggested as a method to 
enhance immunotherapy (Gorczynski et al. 201; Gorczynski et al. 2013; Copland et al. 
2007; Rygiel et al. 2012). A clinical trial sponsored by Alexin Pharmaceuticals 
(NCT00648739) developed a monoclonal anti-CD200 (ALXN6000) to block tumor-
derived CD200 expressed on B-cell Chronic Lymphocytic Leukemia (B-CLL) and 
Multiple Myeloma cells from interacting with CD200R+ lymphocytes 
(clinicalTrials.gov) (Rygiel et al. 2012). No results have been posted in clinicaltrials.gov. 
We do not anticipate that this method will be a very efficacious therapy. Twito et al. has 
demonstrated that “A Disintegrin And Metalloprotease” enzyme (ADAM28) sheds 
CD200 from B-CLL (Twito et al. 2013), which would invalidate the use of an antibody to 
block tumor-driven CD200-CD200R interactions. Our preliminary data corroborates 
Twito’s findings. We reported high transcription levels of CD200 in GBM (Moertel et al. 
2014), however, staining for CD200 protein revealed that, in contrast to normal CNS, 
GBM have low CD200 expression (Figures 9A & B) potentially due to secretion.  
    To validate CD200 protein expression on GBM, human GBM for CD200 
expression were analyzed by western analysis. In contrast to normal CNS tissue, there 
was low expression of CD200 on the tumors. However, closer examination revealed that 
GBMs increase expression of CD200 on endothelial cells within the blood brain barrier 
(Figure 9C). The same CD200 expression was seen in the vasculature of human breast 
carcinoma (Figure 9D) and melanoma (Figure 9E). To determine the ability of GBM to 
upregulates CD200, human endothelial cells (HUVEC) were placed on the bottom of a 
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trans-well plate and human GBM was placed on the top. Following 72hr incubation, 
HUVEC cells were harvested and analyzed by Western Immunoblot (Figure 9F) and RT-
PCR (Figure 9G) for CD200. These experiments demonstrated that GBM induces 

























Figure 9. CD200 is Upregulated in Vascular Endothelial Cells. Tissues isolated from (A) normal 
human central nervous system or (B) glioblastoma multiforme were analyzed for CD200 expression. 
(C) Vascular endothelial cells from normal tissue and glioblastoma multiforme (GBM) (D) breast 
tumor and (E) melanoma cells were analyzed for CD200 expression. Human endothelial cells were 
expanded on the bottom of a trans-well plate. Glioblastoma multiforme cells were placed on the top of 
the plates and incubated for 48hrs. HUVEC were washed and analyzed by (F) western analysis and 
(G) RT-PCR for CD200 transcription. 
 
2.4 Conclusions 
    CD200 has been well described as immunosuppressive, making it a logical target 
for immunotherapy (Moertel et al. 2014). We have been extensively interrogating the 
multiple mechanisms by which CD200 inhibits the development of an anti-tumor 
response. We suggest that the CD200 in tumor-derived vaccines and that the CD200 
protein is secreted from the tumor microenvironment will inhibit the ability of antigen-
presenting cells to mount an anti-tumor response (Figures 10A&B). We also argue that 
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our CD200 peptide inhibitor, through the activation of a CD200 isoform receptor, 
reverses CD200-induced suppression (Figure 10C).  
    Our model is supported by studies reporting that CD200/CD200R interactions 
have been characterized as inhibitory receptor (Gorczynski et al. 2004). CD200R 
contains tyrosine motifs which signal through the recruitment of Dok 2 to distinguish the 
CD200R from almost all other inhibitory receptors that have immunoreceptor tyrosine-
based inhibition motifs. (Hatherley D, et al. 2013) However, additional CD200R-like 
proteins have recently been identified in mice and humans. (Wright et al. 2003) Four 
separate CD200 receptor genes have been identified: CD200R, CD200R2, CD200R3, and 
CD200R4 (Voehringer et al. 2004). These receptors are predicted to be associated with 
DNAX activating protein, (DAP12), known to potentiate and attenuate activation of 
leukocytes (Turnbull et al. 2007). Although the CD200R isoforms have not been well 
characterized, Gorczynski (2008) reported that specific peptide sequences within the 
CD200 protein act as antagonists. Gorczynski hypothesizes that these peptide sequences 
bind to one of the CD200R isoforms that normally contribute an activation signal 
(Gorczynski et al. 2008).  
    Our data correlates with Gorczynski’s hypothesis. We suggest that our CD200 
inhibitor is targeting one of the activation isoforms of the CD200 receptor. However, 
CD200 has multiple mechanisms of inducing immune suppression. Following close 
examination of CD200 immunohistochemistry, we have demonstrated that CD200 is 
upregulated on vascular endothelial cells (Figure 9C). CD200+ endothelial cells appear to 
be tumor-specific because the surrounding CNS does not express CD200 in the blood-
brain barrier vasculature (data not shown). This is an important discovery because others 
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have reported that tumor-CD200 expression differentiates CD4+CD200R+ cells into a 
suppressor T-regulatory population (reviewed in Holmannova, et al. 2012). We suggest 
that CD200R-bearing leukocytes will interact with CD200+ endothelial cells to 
differentiate CD4+CD200R+ to regulatory T cells, leading to the development of an 




























Figure 10. Experimental Models. (A) CD200 from tumor lysates or apoptotic bodies used for 
vaccines binds to the CD200R on antigen presenting cells within the vaccine site inhibiting the 
development of an antitumor response. (B) CD200 is solubilized from tumors binding to CD200 
inhibitory receptors on antigen-presenting cells in the draining lymph nodes inhibiting the 


















inhibitor binds to the CD200 isoform activation receptors, over-riding the inhibitory signals of the 
CD200 protein. (D) CD200+ endothelial cells within the vasculature bind to CD200R+ lymphocytes, 




2.5 Future Plans 
 
Breaking CD200/CD200R interactions intensifies the success of antitumor therapy. We 
developed a 13 amino acid CD200 peptide inhibitor that, given with tumor lysate, 
significantly enhances immunogenicity in our glioma model, as well as our breast 
carcinoma model. We are now focusing our efforts on a mechanism to overcome the 
suppressive CD200+ endothelial cells (Figure 9C). We are developing a monoclonal anti-
CD200R specific for the same epitope as our CD200 inhibitor, which we hope will block 
the differentiation of immune suppressor cells. We hypothesize that, following T-cell 
activation, systemic inoculation of the anti-CD200R will bind the CD200R on CD200R+ 
leukocytes. Our preliminary data suggests that blocking CD200R will allow CD200R 
leukocytes to enter the tumor microenvironment, escaping differentiation into their 
suppressive populations.  
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Binding Analysis of the CD200 Activation Receptors 
3.1 Introduction 
While advances in cancer immunotherapy have occurred over the past two 
decades, the strategies developed by tumors to circumvent immune surveillance and 
tumor-mediated immunosuppression constitute a critical hurdle for the development of 
successful immunotherapies (Ribatti 2017). This is unquestionably true for malignant 
brain tumors such as glioblastoma multiforme (GBM). The immunosuppression observed 
in GBM is mediated by various mechanisms including the accumulation of myeloid-
derived suppressor cells (MDSC), T-regulatory cells and tumor-associated macrophages 
(TAMs), immuno-suppressive cytokine milieu, and the expression of program death-
ligand 1 (PD-L1) by tumor cells and MDSCs (Koyama, et al. 2016 ). These 
immunosuppressive mechanisms have contributed to the modest efficacy of 
immunotherapies for GBM patients, suggesting that further research is needed to improve 
therapeutic efficacy (Garber, et al. 2016; Dine, et al. 2017).  
    Immune checkpoint inhibitors are at the forefront of immunotherapy development 
resulting in unparalleled success in cancer therapy due to their broad bioactivity across 
many tumor types (Curran, et al. 2010; McGranahan, et al. 2016). Among the immune 
checkpoint blocking strategies, the two most clinically successful to date are targeting 
cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and the interaction between 
programmed cell death protein 1 (PD-1) and its ligand 1 (PD-L1). However, one of the 
hallmarks of GBM is tumor heterogeneity, which is mostly characterized by distinct 
genetic alterations that occur in individual tumors originating in the same organ, and 
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tumor cell plasticity as a new source of cancer stem cells, impeding the success of 
immune checkpoint inhibitors in the treatment of GBM (Wieser, et al. 2018). 
     In a disease such as glioma, tumor heterogeneity hinders immunotherapy through 
the activation of different immune checkpoints. 
This may be related to redundancy of activating 
and inhibitory molecules targeted by immune 
checkpoint inhibitors (Koyama, et al. 2016). 
Therefore, multiple inhibitors targeting more 
than one immune checkpoint pathway have been 
employed, significantly enhancing survival. 
Unfortunately, these therapies often cause severe 
immune-related adverse events, often leading to 
treatment discontinuation, hospitalization, or 
even death (Markman, 2018; Hoffmann and Del 
Mar 2015).Our research is focused on the 
development of immunotherapeutic vaccines 
against GBM (Olin, et al. 2014a; Ohlfest et al. 
2013; Xiong, et al. 2016), and on methods to target the immunosuppressive CD200 
protein. The CD200 immune checkpoint regulates the immune system through paired 
receptors inducing inhibitory and activation signals (Kojima, et al. 2016). The inhibitory 
signal is due to the specific binding of the native form of the CD200 protein to the 
inhibitory receptor, CD200R1 and CD200-like receptors termed activation receptors 
(CD200AR) (Wright, et al. 2003). However, in contrast to the inhibitory receptor, the 
Figure 1. Experimental Model. CD200 is 
secreted from tumor cells, and binds to the 
CD200 inhibitory receptor, shutting down the 
immune system. However, CD200 is subjected 
to proteases, altering the folding and releasing 
peptide fragments exposing epitopes from the 
CD200 protein capable of binding to the 
CD200 activation receptors. The activation 
receptors have adjuvant-like properties and 
when stimulated, surmount the inhibitory 
signals activating the immune cells.  
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function and ligands inducing activation receptors have not been defined. There are four 
separate CD200AR genes in mice; CD200AR2, CD200AR3, CD200AR4, and 
CD200AR5, (Gorczynski, et al. 2004, Voehringer, et al. 2004), and two in humans; 
CD200RL1 and CD200RL2 (Wright et al. 2003). Although the CD200AR have not been 
well characterized, Gorczynski reported that specific peptide sequences bind to 
CD200ARs that contribute an activation signal attenuating the activation of leukocytes 
(Gorczynski, 2005; Gorczynski, et al. 2008) (Figure 1).  
Several rigorous studies have provided evidence that targeting CD200 will 
enhance immunotherapy (Rygiel, et al. 2012; Copland, et al. 2007). We hypothesize that 
targeting the CD200 checkpoint will surmount the immune suppression produced by the 
tumor-derived CD200 protein. We developed peptide ligands to target the CD200AR 
(CD200AR-L). Peptides have advantages over proteins and antibodies as drug candidates 
because of their ability to penetrate further into tissue (McGregor, 2008), higher activity 
per unit mass, greater stability, and reduced potential for nonspecific binding resulting in 
decreased toxicity (Ladner, et al. 2004). Peptides are increasingly being developed to 
treat cancers including Cilengitide for GBM, Zaltrap for colon and Degarelix for prostate 
cancer. A recent search on ClinicalTrials.gov revealed over 50 actively recruiting or 
completed trials using peptide vaccines, 13 of which targeted CNS tumors supporting the 
feasibility of this approach.   
We reported that the use of CD200AR-L in addition to tumor lysate vaccines 
significantly enhanced survival in a murine glioma model (Xiong, et al. 2016) and 
survival in a pilot trial in pet dogs with spontaneous high-grade glioma (Olin, et al. 2019). 
Specific binding of the CD200AR-L to the various receptor(s) remained unknown. 
 52 
Therefore, we sought to use a macrophage cell line to knock out the CD200ARs. The 
binding of ligands to CD200ARs eliciting an immune response need to be determined. In 
this chapter, we report the development of a monocyte cell lines in which we 
systematically knocked out CD200ARs to generate macrophages expressing different 
CD200 receptors, singly or in combination. These cell lines allowed us to demonstrate 
binding between the CD200AR-L and specific CD200ARs and validate cell activation.  
 
3.2 Results 
3.2.1 Characterizing the Macrophages (Raw 264.7 MÆs) 
To initiate our studies, we first characterized a macrophage (Raw 264.7) cell line. 
In these studies, RNA was isolated from MÆs to analyze the constitutive levels of the 
different CD200 receptors (Figure 2A). We confirmed that Raw 264.7 MÆs express all 
of the CD200 receptors. Next, we wanted to demonstrate that the peptide would bind to 
the cells. To accomplish this, we developed a biotinylated CD200AR-L (B-CD200AR-L) 
peptide to pulse macrophages and following incubation, cells were stained with a 
streptavidin alexafluor-568 conjugate and analyzed with microscopy (Figures 2B-D). Un-
pulsed cells stained with Alexafluor-568 conjugate were used as a control (Figures 2E-
G). We saw fluorescence on the cell surface of the MÆs pulsed with B-CD200AR-L, but 
no fluorescence was noted on stained MÆs with pulsed with non-biotinylated CD200AR-
L or the un-pulsed controls. These findings validate that CD200AR is located on the MÆ 
cell surface and binds CD200AR-L. To test if biotinylation affected activity, wildtype 
macrophage cells were pulsed with the B-CD200AR-L and the functional response was 
assessed. Macrophages pulsed with nonbiotinylated CD200AR-L and un-pulsed cells 
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were used as controls (Figure 2H). The cells pulsed with B-CD200AR-L induced TNFα 
production that was not significantly different than the cells pulsed with non-biotinylated 
CD200AR-L. This demonstrated the ability to use the B-CD200AR-L to identify the 
CD200ARs is associated with natural CD200AR-L. In conclusion, these findings 
demonstrated that the CD200ARs are expressed constitutively in MÆs, and that the B-






























































Figure 2. Characterizing the Macrophages (Raw 264.7 MÆs). A) To determine the gene 
expression of CD200ARs, RNA from 106 unstimulated macrophages was analyzed using qPCR. The 
relative expression of each CD200ARs was calculated after being normalized with the housekeeping 
gene GAPDH. (B-G) Macrophage were pulsed with 10 uM biotinylated P1 (B-CD200AR-L) peptide, 
then cells were stained with streptavidin Alexa fluor 568. Stained MÆs with streptavidin or DAPI 
alone were used as control (H) In a separated experiment, macrophages were pulsed with 10uM ligand 
B.         DAPI C.    Streptavidin            D.        Merged 
E. DAPI F. Streptavidin              G.        Merged 
































for 48h. Then, the supernatant was collected to determine TNF-a secretion. Error bars are ± SEM, 
asterisks represent a statistical significance *p < 0.05, **p = 0.005 or ***p = 0.0005 determined by 
multiple t test one per row. 
 
3.2.2 Generation of Knockout Macrophages 
Now that we had a macrophage cell line to assess binding, CD200AR knockout cell 
lines were developed. To accomplish this, CRISPR guide RNAs (sgRNAs) were 
designed using online tools (http://genome-engineering.org) to target the exon 3 of either 
CD200R1 or CD200AR2, exon 2 of CD200AR3, and exon 4 of CD200AR4.  Cells were 
transfected and sorted three times and sorted on a FACSAria II cell sorter (BD 
Biosciences, University of Minnesota Flow Cytometry Facility). PCR was used to 
confirm gene removal (Figures 3 C-E) and non-transfected cells were used as controls.  
First, a single CD200 receptors knockout were derived from the wildtype macrophages to 
get CD200R1, CD200AR2, CD200AR3, and CD200AR4 knock out, and from these, 
different macrophage cells lines described below were developed: 
 
• SingleCD200R1KO (PCR validation Fig. 3A 
lane 1) cells were used to remove the 
CD200AR2 gene (PCR validation Fig. 3B 
lane 1) to derive CD200R1 CD200AR2 
double KO cell line (expressing CD200AR3 
and AR4). These cells were further used to 
knock out CD200AR4 (PCR validation Fig. 3C lane 5) resulting in a cell line that 












• Single CD200AR2KO (PCR validation 
Fig. 3A lane 3) cells were used to remove 
the CD200AR3 gene (PCR validation Fig. 
3B lane 3) for the development of 
CD200AR2 and CD200AR3 double KO 
cell line (expressing CD200R1 and 
CD200AR). These cells were further used 
to knock out CD200R1 (PCR validation Fig. 3C lane 2) resulting in a cell line that 
expressed CD200AR4 alone.  
 
• Single CD200AR3KO (PCR validation Fig. 3A 
lane 4) cells were used to knock out the 
CD200R1 gene (PCR validation Fig. 3B lane 2) 
resulting in the development of  a CD200R1 and 
CD200AR3 double KO cell line (expressing 
CD200AR2 and CD200AR4) that was then used 
to knock out the CD200AR4 gene (PCR 
validation Fig. 3C lane 5) creating a cell line 













• Single CD200AR4KO (PCR validation Fig. 
3A lane 5) cells were used to knock out the 
CD200AR3 gene (PCR validation Fig. 3B 
lane 3) resulting in a CD200AR3 
CD200AR4 double KO cell line 
(expressing CD200R1 and CD200AR2). 
This cell line was used to knockout the 
CD200AR2 (PCR validation Fig. 3C lane 3) to develop a cell line expressing 
CD200R1 alone. 
 
• Single CD200AR4KO (PCR validation Fig. 3A lane 
5) cells were used to knock out the CD200R1 gene 
(PCR validation Fig. 3B lane 2) resulting in a 
CD200R1 CD200AR4 double KO cell line that 
expressed CD200AR2 and CD200AR3 (Figure 3C).  
 
These experiments allowed us to derive the unique cell lines expressing different CD200 
receptor. All receptor knockout cell lines were sequenced to validate gene removal. 
Additionally, all cells with receptors R1, AR3 or AR4 knocked out were validated by 
flow cytometry, however flow could not be done for the AR2KO since no antibody for 
CD200AR2 is available.  
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Figure 3. Establishing the CD200 Receptor Knockout Macrophages.  The system CRISPR/Cas9 
was used to generate CD200 receptors knockout macrophages. A-C PCR validation was performed to 
determine the deletion of CD200AR genes. 
 
3.2.3 Murine CD200AR-L Activates CD200AR2&3 and CD200AR3&4 
With developing of a model to study the peptide CD200AR-L/CD200AR binding, we 
pulsed the macrophages with B-CD200AR-L. In contrast to the wildtype cells (Figure 
4A), reduced peptide binding was seen on CD200AR2KO and CD200AR3KO and no 
peptide binding was observed on CD200AR4KO cells.  Cells expressing different 
combinations of two CD200ARs. Were pulsed demonstrating strong peptide binding on 
these cells expressing CD200AR2&AR3, CD200AR3&AR4 and CD200AR2&AR4 
(Figures. 4E&G).   
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Figure 4. CD200AR-L Binds to CD200AR Complexes. (a) wildtype, (b) CD200AR2KO, (c) 
CD200AR3KO, (d) CD200AE4KO, (e) CD200AR2&3 expressing, (f) CD200AR-2&3 and (G) 
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3.2.4 CD200AR-L Primarily Signals through the CD200AR2&3 Complex  
The functional effects of CD200AR-L binding to the different CD200ARs were 
determined by pulsing with CD200AR-L and analyzing supernatants for cytokine 
production. These experiments correlated with the binding experiments in that only the 
pulsed cells expressing a combination of two CD200 activating receptors induce TNFα 
secretion (Figure 5A), surprisingly, cells expressing the CD200AR2, 3 & 4 receptors do 
not induce TNFα secretion (data not shown). However, the CD200AR2&3 cells had a 
significant increase in IL-12 production (p=0.012) and both CD200ARs 2&3 and 
CD200AR2&4 cell lines had a significant increase in TNFα (p=0.039, p=0.032, 
respectively) and IL-6 (p=0.006, p=0.02, respectively) expression. In addition, only cells 
expressing CD200AR2&3 complexes had a significant increase of MCP-1 (p=0.005) 
(Figure 5B-E).  The findings are shown here demonstrated that the ligand CD200AR-L 
primarily targets the CD200AR2&3 complex. However, there was also a lesser response 
by the CD200AR2&AR4 complexes activating antigen-presenting cells. It is known that 
activating immune receptors comprised of multiples subunits that can mix and match 
those subunits and allow a cell to construct varying receptor complexes with different 
ligand specificity. These results show that innate cells, like macrophages, build distinct 
CD200AR complexes with different binding affinities to maintain homeostasis of the 
immune system. This is an important mechanism of how the immune system balances 
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Figure 5. CD200AR-L Primarily Signals through the CD200AR2&3 Complex. (A) CD200AR 
macrophage cell line expressing single CD200ARs were pulsed with the CD200AR-L and analyzed 
for TNFα CD200 macrophage cell lines expressing duel CD200ARs were pulsed with the CD200AR-
L, supernatants were analyzed for (B) IL-12, (C) TNFα, (D) IL-6 and (E) MCP-1. Error bars are 
representative of standard deviation (n=3/group *P < 0.05 and **P<0.005; by t-test.    
 
3.3 Discussion   
There have been contradictory reports regarding binding of CD200 to the 
CD200ARs and whether that the binding triggers immune activation. (Gorczynski, et al. 
2004; Hatherley et al. 2005). Wright et al. (2003) reported that mCD200RLa 
(CD200AR4) and mCD200RLb (CD200AR3) do not bind mCD200. Additionally, 
Hatherley et al. (2005) showed proteins expressed at the cell surface and directly at the 
protein level that the soluble CD200 did not bind to CD200ARs.  These two groups 
concluded that the ligands for CD200 activation receptors were unknown. Conversely, 
Gorczynski, et al. 2004 reported that soluble CD200 binds to CD200AR expressed in 
COS7 cells providing the first evidence that members of the CD200R family other than 
CD200R1 can bind CD200. Moreover, CD200-derived peptides may discriminate 
between CD200R1 or other CD200ARs and regulate inhibitory and activating functions, 
as defined by the immunological context (Gorczynski, et al. 2008). Overall, a better 
understanding of the ligation of CD200ARs expressed on myeloid cells and its 
immunological consequences is needed.  
We have demonstrated receptor specificity of the CD200AR-L and the functional 
interplay between CD200AR complexes. These studies show that cells expressing 
CD200ARs 2&3 primarily responded to stimulation by CD200AR-L while cells 
expressing receptor combinations of 1,2&3, 1,3&4 or 2,3&4 failed to respond. In earlier 
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report, we described the development of three murine CD200AR-Ls based on previously 
published peptides (Xiong et al. 2016; Moertel et al. 2014) that provided different 
survival results in a murine glioma model. This may explain our observation that CD200-
derived peptides bind with different ligand specificity to a duplex-complexes of 
CD200ARs and induce differences in a survival benefit in our breast carcinoma and 
glioma murine models. (Moertel, et al. 2014). This data shows that CD200ARs form 
complexes to interact with the peptide ligands to optimize the biological function of 
macrophages. It also shows that CD200-derived peptides function protectively in our 
mouse model of glioma because the CD200AR-L binding to a complex of two CD200 
activation receptors on innate immune cells like macrophages so induces immune 
activation that could overcome the negative signal of the CD 200 protein.   This data is in 
agreement with previous reports that CD200-derived peptides designed to target the 
different CD200ARs modulate inflammatory processes in vivo in a selective manner 
(Gorczynski, et al. 2008).  
 
3.4 Materials and Methods 
Transfection: Raw 264.7 MÆs were transfected using Neon electroporation system 
(Invitrogen). Briefly, Raw 264.7 MÆs were grown in RPMI 1640 supplemented with 
10% fetal calf serum, 1% penicillin/streptomycin, and incubated at 370C until 80% 
confluent. Cells were harvested by trypsinization, washed once in RPMI and resuspended 
in 1X PBS at a concentration of 5e106 cell density (cells/ml). Then, 10ul cells were taken 
for the transfection. Ten ul of suspension cells was precipitated and resuspended in 10 ul 
Neon Buffer R, mixed with 1 ul (1ug/ul) Clean-Cap Cas9 mRNA (TriLink 
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Biotechnologies) and 1 ul (100 pmol/ul) CRISPRevolution sgRNA Synthego (Synthego) 
and incubated for 2 min. Transfection conditions were 1,720 pulse voltage, 10 pulse 
width, and 2 pulse numbers. Two days after transfection, a PCR was performed, and the 
PCR products were sequenced to validate the deletion. Cells were assessed for expression 
status by flow cytometry. CD200R1 was assessed by staining with PE-conjugated OX-
110 (Biolegend), and CD200AR3 was assessed by staining with APC-conjugated Ba13 
(Biolegend).  
Immunofluorescence Cell-Binding assay: 5 X104 macrophage were grown in a Lab-
Tek II 8 chamber slide in 200 ml RPMI containing 10% calf serum and 1% 
penicillin/streptomycin. Following ~70% confluency, cells were washed twice with 1X 
PBS and pulsed with 10uM biotinylated peptide ligand for an hour fixed in 4% PFA for 
20 min at RT then incubated with streptavidin alexafluor 568 conjugate (Thermo Fisher 
Scientific) for 1 h, washed with 1X PBS and stained with 1ug DAPI. Imaging was 
performed using the Nikon Inverted TiE Deconvolution Microscope System (University 
of Minnesota). 
Cytokine Secretion: Unless otherwise stated, all cells were treated at the same 
conditions for the cytokine secretion. A total of 1 × 106 cells was grown in 0. 500 ml in 
RPMI-1640 in a 48-well plate for 12 h, then pulsed with 10uM ligand P1, and incubated 
for an additional 48 h.  LPS (1uM) and non-pulsed cells were used as controls.  
Supernatant (50ul) were collected and analyzed for TNFα levels using cytometry bead 





Unraveling the Signaling Pathways of the CD200AR 
4.1 Introduction 
Paired receptors are cell surface proteins expressed primarily on immune cells 
containing conserved extracellular domains capable of eliciting either inhibitory or 
stimulatory signals (Humphrey et al. 2005). The inhibitory receptors have long 
immunoreceptor tyrosine-based inhibitory motifs (ITIM) within the cytoplasmic region 
(Daeron, et al. 2008). Conversely, activation receptors usually have short cytoplasmic 
tails. These short tails contain positively charged lysine or arginine residues in their 
transmembrane domain to associate with adaptor proteins possessing immunoreceptor 
tyrosine-based activation motifs (ITAM) including DAP12, CD3, CD79, and FcR that 
provide tyrosine-based activation motifs as docking sites for downstream signaling 
(Isakov, et al. 1997). In addition to the ITAM signal, there is a tyrosine-based signaling 
motif (YINM), which is present in the adaptor protein DNAX-activating protein of 10 kD 
(DAP10) and it is known that DAP10 coop with some immune activation receptors like 
NKG2D, Ly49H, and Ly49D. 
Unlike the inhibitory receptor, CD200R1, CD200ARs have a positively charged 
lysine residue within their transmembrane-spanning regions, may recruit signaling 
molecules directly, and are thought to function by coopting accessory molecules (Wright 
GJ, et al. 2000, Wright, et al. 2003, Kojima, et al. 2007). In vitro studies have shown that 
two CD200 activation receptors, CD200AR4 and CD200AR3, coopt with the adaptor 
protein, DAP12, suggesting that these receptors could transmit strong activating signals 
(Wright et al. 2003; Voehringer, et al. 2004). However, a connection between recruitment 
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of the CD200ARs and DAP12 has not been established (Voehringer, et al. 2004). 
Therefore, the role of DAP12 or other adaptor protein relative to CD200 activating 





Figure 1. Proposed DAP12 Signaling Pathway in Macrophages and Osteoclasts. In response to 
ligation of TREM2, Src family kinases phosphorylate the ITAM of DAP12 and the YINM motif of 
DAP10, which form docking sites for the Syk and p85, with the subsequent recruitment of PLC-γ2 
and Grb2. This signaling complex then leads to the activation of Akt, ERK1/2, and Vav3. 
Simultaneously, SHIP1 is recruited to the DAP12 ITAM where it may dislodge or prevent the further 
recruitment of SH2 or SH3 domain–containing proteins, including p85 and Syk respectively. This 







The initial studies into the signaling pathways involved with the CD200AR-
L/CD200AR binding focused on DAP10 due to its association with the DAP12 pathway 
(Lanier et al. 2009). DAP10 is a transmembrane signaling adaptor that has a short extra-
cytoplasmic domain and no known ligand-binding properties and is predominantly 
expressed in immune cells, including NK cells, T cells, and monocytes (Figure 1) (Wu et 
al. 1999; Chang et al. 1999). DAP10 does not have a cytoplasmic ITAM, but it displays 
an YINM motif that couples to phosphatidyl-inositol 3-kinase (PI3K) dependent 
pathways (Nicolas et al. (2003). Moreover, it is reported that human NKG2D-DAP10 
triggers cytotoxicity (Wu et al. 2000; Billadeau et al. 2003) and mediates primary 
stimulation signals in addition to co-stimulatory signals in NK cells (Billadeau et al. 
2003; Zompi et al. 2003). 
 DAP12 is a 12-kD homodimer plasma membrane that associates with numerous 
receptors through paired charged amino acid residues within the transmembrane domains 
(Peng et al. 2010).  In myeloid cells, several DAP12-associated receptors have been 
identified. These receptors fall into two categories: members of the immunoglobulin 
domain superfamily, such as triggering Receptor Expressed on Myeloid cells 1 (TREM-
1), triggering Receptor Expressed on Myeloid cells 2 (TREM-2), triggering Receptor 
Expressed on Myeloid cells 3 (TREM-3), myeloid-associated immunoglobulin-like 
receptor II (MAIR-II), CD200 activation receptor 4 (CD200RLa), signal-regulatory 
protein beta (SIRP-β) and paired immunoglobin-like type 2 PILR- β; and members of the 
C-type lectin family, such as myeloid DAP12-associating lectin 1 (MDL-1) and mouse 
NKG2D-short (Lanier et al.  2019, Peng et al. 2010).  
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Some studies showed that DAP12 is required to down-regulate Toll-like receptor 
(TLR)–induced production of cytokines to limit inflammatory responses in vivo 
(Hamerman et al. 2005, 2006) suggesting that DAP12 may have both inhibitory and 
activating functions. Previous reports have shown that CD200ARs pair with DAP12 but 
they failed to demonstrate an effector immunological function. Thus, whether DAP12 
inhibits or activates the immune biological functions of the CD200Ars is unknown.  
Intracellularly, DAP12 does not have signal-transducing elements other than a 
single ITAM, which recruits and activates Syk in myeloid cells following tyrosine 
phosphorylation and Syk and ZAP70 in NK cells (Lanier et al. 2008). Moreover, like the 
CD3 and CD79 subunits, DAP12 has an acidic amino acid (aspartic acid) embedded 
within its transmembrane region allowing stable, non-covalent complexes with its 
associated receptors (Lanier et al. 2009).   
In summary, in the previous chapters, we demonstrated that a peptide ligand 
(CD200AR-L) bind to CD200AR complexes leading to the activation of macrophages 
and cytokines secretion, however, the signaling pathways that result in immune activation 
remain unknown. Therefore, we performed ingenuity pathway analysis (IPA) on wildtype 
naïve-CD11b cells pulsed with CD200AR-L. The results of this analysis, in conjunction 
with current literature, led to the development of the hypothesis that CD200 activation 
receptors recruit and signal through the DAP10 and DAP12 pathways. In this chapter, we 
will test our hypothesis by addressing these specific aims: i) interrogate at transcriptional 
level the response of DAP10 and DAP12 over time in wildtype CD11b cells pulsed with 
CD200AR-L, ii) assess for the presence of the downstream signaling molecules of 
DAP10 pathway and their ability to knock down transcription using selected inhibitors, 
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iii) we suggest that the CD200AR may pair with DAP10 or DAP12 or both to activate 
antigen-presenting cells since DAP10 and DAP12 have been reported to form complexes 
following activation, hence, we will assess whether complexing of DAP10 and DAP12 
occurs after CD200AR ligation, and iv) assess the in vitro and in vivo the effects of 
DAP10 and DAP12 pathways.    
 
4.2 Results 
4.2.1 Ingenuity pathway Analysis (IPA) Suggests CD200AR-L Signals through the 
DAP10 Pathway 
Following optimization of the CD200AR-L (described in chapter 2), we wanted to 
determine the signaling pathway utilized by the CD200ARs.  To accomplish this, CD11b 
cells isolated form wildtype mice were pulsed with the CD200AR-L for 1h.  Data was 
analyzed using (IPA) (Qiagen) and revealed an upregulation of multiple signaling 
molecules downstream of DAP10 leading to the development of our experimental model 
shown in Figure 2. These experiments suggest that the ligand CD200AR-L induces of 




Figure 2. The CD200 Derived Ligand CD200AR-L activates the Canonical DAP10 Signaling. 
CD11b cells isolated from wildtype mice, pulsed with 10uM CD200AR-L for one hour. Then RNA 
was harvested and analyzed using NanoString technology. Data analysis and interpretation to identify 
the immune pathways were done using ingenuity pathway analysis (IPA) (table 1), and immune 
molecules DAP10 related are highlighted on a red-square (A) and leading to our experimental model 
of the immune activation of APC/macrophages (B). 
 
4.2.2 CD200ARs Signal through Dap10 and DAP12 Molecules.  
We next wanted to validate the IPA analysis suggesting that CD200AR 
stimulation could initiate DAP10 or DAP12 signaling pathways. According with the gene 
expression profile results, CD200AR-L induced gene expression of DAP10 and DAP12 
for 1 h then cells send re-stimulation signals upregulating DAP10 and DAP12 12 hours 
later (Figure 3A). To validate transcription expression, in separate experiments, CD11b 
cells isolated from wildtype mice were pulsed with the CD200AR-L at 1, 3, 5, 7, 15, 30 







































quantitate these results, density was measured (Figure 3C) and normalized compared to 
non-pulsed (Figure 3D).  Results were consistent with the model where, immune-
activating  
receptors recruit DAP10 and DAP12 molecules to deliver positive signals since DAP10 











































































































Figure 3. CD200AR-L Induces DAP10 and DAP12 Molecules. CD11b cells isolated from wildtype 
mice were pulsed with 10 uM CD200AR-L at different time frame and analyzed for (A) DAP10 and 




4.2.3 CD200AR-L Activates the DAP10 Cascade 
To further validate our studies, we next evaluated the gene expression profile of 
the DAP10 signaling molecules upon stimulation of APC/macrophages with CD200AR-
L1. To accomplish this, wildtype cells were pulsed for 6 hrs with the CD200AR-L, RNA 
was extracted and analyzed for expression of downstream signaling molecules (Figure 
4A). We confirmed upregulation of the expression of DAP10 signaling molecules in 
murine CD11b, SLP76 and VAV1, which are functional effector downstream of DAP10, 
were mainly up-regulated. These experiments demonstrated the activation of signaling 
molecules downstream of the DAP10/DAP12 pathways. Next, we designed an inhibition 
assay to determine specific signaling molecules downstream of the DAP10/DAP12 
pathway, CD11b cells were stimulated with 10uM CD200AR-L +/- theCD200AR-L 
(10uM) P38MAPK inhibitor (SB203580) (Figure 4 G-I) or (10nM) Jak1/Jak3 inhibitor 
(Tofacitinib) (Figures 4J-K), and gene expression analyzed at 0–6h and 0-18h by 
quantitative PCR. As expected from the signaling data reported above, gene expression of 
P38MAPK, ERK1/2, Vav1, SLP76, and Jak1/Jak3 was inhibited. These data 
demonstrated that CD200AR can trigger CD11b activation by a mechanism dependent on 
MAPK kinases. Taking together, these findings suggest that CD200ARs control CD11b 
cell activation via a previously unknown regulatory pathway that is, a PI3-K-dependent, 
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Figure 4. CD200AR-L Activates the DAP10 Cascade. CD11b cells isolated from wildtype mice 
were pulsed with P1CD200AR-L for 6h, (A) RNA was isolated and analyzed for various signaling 
molecules downstream of the DAP10 pathway. In separate experiments, CD11b cells pulsed for 6 or 
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cJUN. In separate wells, cells pulsed for 6 hours with the P1CD200AR-L + the inhibitor SB203580 
and analyzed for transcription levels of (G) p38MAP, (H) ERK1/2, (I) SLP76 or the CD200AR-L + 
Tofacitinib and analyzed for transcription levels of (J) Jak1 and (K) Jak2. Error bars are representative 
of standard deviation (n=3/group *P < 0.05 and **P<0.005; by t-test.    
 
 
4.2.4 DAP10 and DAP12 Primary Signal through the CD200AR2&3 Complex 
We next asked which CD200ARs primarily signal through the DAP10 or DAP12. 
To accomplish this, we took CD200AR cells expressing the 2&3, 2&4 and 3&4 
complexes and pulsed them with the CD200AR-L. We observed by western analysis that 
ERK ½ signaling was primarily activated through the CD200AR2&3 complex (Figure 
5A). Therefore, we repeated it looking at Vav1 and c-Jun (Figure 5B&C) since Vav1 has 
associated to DAP10 pathway showing the signaling was mainly through the 
CD200AR2&3 complex for Vav1, both CD200AR2&3 and CD200AR2&4 activated c-
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Figure 5. DAP10 and DAP12 Primary Single through the CD200AR2&3 Complex. Macrophage 
expressing CDAR 2&3 (A), 2&4(B) and 3&4 (C) complexes were pulsed with the CD200AR-L. Cells 
were (A-C) analyzed by western analysis, and density bands corresponding to c-JUN (D), ERK1/2 
(E), VAV1 (F) were measured. Error bars are representative of standard deviation (2=3/group *P < 
0.05 and **P<0.005; by t-test).    
 
 
4.2.5 Dap10/Dap12 Complex together 
It has reported that DAP10 forms complexes with DAP12 and coopt with 
immune-activating receptors to signal downstream and activate innate cells. Therefore, 
we assessed whether DAP10/DAP12 forms complexes after CD200AR-initiated 
signaling. In these experiments, CD11b cells from wildtype and DAP10 KO mice were 
pulsed with the CD200AR-L at different times and analyzed for DAP10 (Figure 6A) or 
DAP12 (Figure 6B) by western analysis. These experiments revealed a DAP10 and 
DAP12 band at both 20kD and 24kD respectively but was gone in the DAP10KO CD11b 
cells. To determine if this is a doublet or DAP10/DAP12 complex, CD11b cells isolated 
from DAP10KO mice were analyzed for DAP12 by western (Figure 6C). We observed 
tissue from DAP10KO mice failed to form a complex demonstrating a DAP10/12 
complex.  These findings are in agreement with previous reports, the DAP10/DAP12 
complex coop with immune-activating receptors (Lanier LL, et al. 2009). Moreover, by 
measuring the densities of the western bands revealed that the removal of DAP10 


















































































Figure 6. Dap10/Dap12 Form Complexes. CD11b cells isolated from (A&B) wildtype and (C) 
DAP10KO mice were pulsed with CD200AR-L P1 at various times and analyzed for DAP10 or 





























DAP12 protein levels. Density bands was measured to confirm the DAP10/DAP12 complex. Error bars 
are representative of standard deviation (2=3/group *P < 0.05 and **P<0.005; by t-test).    
 
 
4.2.6 Knocking out the DAP10 and DAP12 Pathways Inhibits CD200AR-L 
Activation 
To assess whether the presence of DAP10 or DAP12 are required for CD11b 
stimulation, CD11b cells were harvested from wildtype, DAP10KO and DAP12KO mice 
and pulsed with the CD200AR-L, supernatants were harvested and analyzed for TNF 
alpha production (Figure 7A). These findings validate our earlier studies demonstrating 
the CD200AR-L signals through DAP10 and DAP12 pathways. We observed that 
knocking out DAP10 and DAP12 inhibited the TNF# production. 
 Therefore, we next sought to determine if these studies translated in vivo. To 
accomplish this, wildtype, DAP10 and DAP12 knockout mice were given tumors and 
treated with tumor lysates (TL) or TL + CD200AR-L. We observed a significant decrease 
in tumor growth in wildtype mice inoculated with TL + CD200AR-L, however, in 
DAP10KO mice, we had a rapid increased in tumor growth in mice receiving TL+ 
CD200AR-L (Figures 7B&C). However, we observed decreased tumor growth in 
DAP12KO mice. Moreover, we observed that the removal of DAP10 significantly 
decreased survival in mice vaccinated with TL + CD200AR-L. These experiments 
determined that the DAP10 pathway is crucial to take control of the tumor growth by 
innate cells through the activation of CD200AR. We believe that DAP12 KO mice 
response to the CD200AR-L similarly to the wildtype mice because of the activation of 
DAP10 signaling pathways through the vaccination of CD200AR-L. Thus, these analyses 
based on both cell stimulation and in vivo study indicate that CD200ARs stimulation on 
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mouse CD11b couple to the signal-transducing subunit DAP10 to generate selective 
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Figure 7. Knocking out the DAP10 and DAP12 Pathways Inhibit P1A12 Activation. (A) CD11b 
cells isolated from murine DAP10KO or DAP12KO or wildtype were pulsed with 10uM CD200AR-L 
for 48h, supernatant was collected and analyzed for TNFα production. To determine the effects of 
DAP10 and DAP12 in vivo, GL261 tumor bearing mice (wildtype (B), DAP10 (C), DAP12 KO (D)) 
were vaccinated with tumor lysates (TL) or TL + CD200AR-L and follow up for survival (E).  Error 
bars are ± SEM, asterisks represent a statistical asterisk represent a statistical significance *p < 0.05, 




Our research focuses on the understudied CD200 immune checkpoint that 
modulates an immune response through paired receptors. Relatively, little is known of 
how CD200 exerts its effector immune functions particularly those regarding its 
activation receptors (Wright et al. 2003; Gorczynski et al. 2004; Voehringer et al. 2004; 
Hatherley et al 2005; Kojima et al. 2007; Lanier et al. 2009). This work shows that 
DAP10 couples to the CD200ARs stimulation and induces the downstream activation of 
phosphatidylinositol 3-kinase, Vav1, ERK1/2 and cJUN. Second, the signals initiated by 































CD200ARs/DAP10 are fully capable of inducing cytokines secretion and controlling 
tumor growth. Third, the axis CD200AR-L P1/CD200ARs/DAP10 elicits 
proinflammatory cytokines, and chemokines, primarily (chapter 3), and these cytokines 
are crucial for the recruitment and trafficking of the immune cells, and the immune cells 
take control of the tumor. Thus, these findings identify a previously unknown mechanism 
by which receptor complexes of CD200ARs that lack ITAM motifs can trigger 
macrophage activation. 
We pulsed CD11b cells isolated from wildtype (C57B6) mice and performed 
NanoString analysis, and data analysis was analyzed using IPA. These studies confirmed 
an upregulation of DAP10 and DAP12 molecules on cells pulsed with CD200AR-L. We 
next repeated the same experiment, but we analyzed the RNA for the DAP10 and DAP12 
gene expression at different times. Interestingly, analyzing the time course determined 
that the DAP10/12 pathway increases within the 1st 5 minutes decreasing signaling after 
an hour, then the pathways are re-activated 24hrs post pulsing.  Moreover, this data 
suggests that CD200AR-L stimulation induces the upregulation of DAP10 immune-
related molecules, particularly, those sufficient to initiate phosphorylation of SLP-76 and 
Vav1 and MAPK kinases phosphorylation. These results explain our vaccination results. 
We determined that vaccinating mice with the peptide with tumor lysates enhanced 
survival, however, we determined that survival is significantly enhanced if we vaccinate 
the animals with the CD200AR-L then 24hrs later revaccinate with the CD200AR-L + 
tumor lysates (Moertel et al. 2014, Xiong et al. 2016, Olin et al. 2019).  These 
experiments demonstrated the cell has a feedback loop re-stimulating the DAP10/12 
pathways enhancing cell activation.   
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Although the DAP10 and DAP12 are independent pathways, they are thought to 
form complexes with each other to enhance and maintain signaling (Gilfillan et al. 2002). 
In response to ligation of TREM2, Src family kinases phosphorylate the ITAM of DAP12 
and the YINM motif of DAP10, which form docking sites for the Syk and p85, with the 
subsequent recruitment of PLC-γ2 and Grb2 (Fig 1) (Tassi I, et al. 2006). We observed 
what we originally hypothesized as a dimerization of the DAP 10 and DAP12 bands in 
our western analysis. However, following a search in the literature, DAP10 and DAP12 
forms cysteine bonds (Rabinovich et al. 2006).  Therefore, we took DAP10KO CD11b 
cells pulsed with the CD200AR-L and analyzed them by western for DAP12. We 
observed the same DAP12 band at 12kD as observed in the wildtype cells, however, the 
band at 23 kD originally thought to be a dimer of the DAP12 validated that DAP10 and 
DAP12 bond together following activation. Hence, the CD200AR-L induces the 
activation of DAP10/DAP12 complex on antigen-presenting cells. 
To further validate the role of DAP10 and DAP12 signaling pathways, we 
isolated CD11b cells from wildtype, DAP10 and DAP12 mice and pulsed them with the 
CD200AR-L. These experiments revealed a loss of function response to the CD200AR-L 
measured by TNFα production. Therefore, we wanted to determine if the benefit of using 
the CD200AR-L was lost in our tumor-bearing immunotherapy. We observed a 
significant reduction in wildtype mice and DAP12KO mice. However, we observed a 
significant increase in tumor growth in DAP10KO mice. These experiments 
demonstrated the importance of DAP10, although DAP12 is involved in CD200AR 
signaling, we suggest the ability to maintain a reduced tumor growth in DAP12KO mice 
was due to the DAP10 pathway. Moreover, we hypothesize the increased tumor growth 
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in DAP10KO mice is due to the ability to induce a cytolytic response.  It is reported that 
human NKG2D-DAP10 triggers receptor for cytotoxicity in NK cells (Billadeau et al. 
2003) and mediates primary stimulation signals, not only co-stimulatory signals, in NK 
cells (Lanier et al. 2019; Peng et al. 2010). Therefore, we lack the NK response capable 
of eliminating the tumor in DAP10KO mice. These studies correlate with our current 
studies showing that tumor-spontaneous-regression occur in CD200KO GL261 bearing-
mice around 14d post-inoculation and have high NK infiltration (data not shown). 
 
4.4 Materials and Methods 
 
Animal housing: C57BL/6 mice were purchased from Jackson Laboratories (Bar 
Harbor, ME). DAP10 and DAP12-deficient mice were a generous gift from Dr. Lewis 
Lanier (University of California). Mice were housed in the specific pathogen-free animal 
facility at the University of Minnesota, according to institutional guidelines.  
 
Brain inoculation:  8 to 16 week-old mice were anesthetized with an intraperitoneal 
injection of 0.03 ml ketamine HCl (100mg/mL)/xylazine (20mg/mL). For the stereotactic 
intracranial injection, the surgical site was shaved and prepared with 70% ethyl alcohol. 
Mice were placed in a stereotactic frame and a midline incision was made with a scalpel. 
A 1 mm burrhole was made 0.5 mm anterior to the bregma and 2.5 mm to the right of the 
midline. A Hamilton micro-syringe was inserted to a depth of 3 mm and withdrawn to a 
depth of 2.5 mm. 14 × 103 cells of GL261-Luc+ in 1ul saline was inoculated over four 
minutes. The needle was removed, and the skin was sutured with 4-0 nylon thread. 
Immediately after surgery, mice were injected with 5mg/Kg Carprofen and followed by 
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heating system. In addition, mice were administrated with Carprofen 5mg/Kg three days 
following tumor inoculation. 
 
Vaccination schedule: Wildtype, DAP10KO or DAP12KO GL251-Luc+ mice (n=5) 
were vaccinated subcutaneously in back of the neck as described in figure 8. Mice 
received i) 65ug tumor lysate or ii) 65ug tumor lysate + 50 ug of P1, iii) saline treated 




Bioluminescence Monitoring of Tumor Growth: Bioluminescence imaging was done 
weekly, beginning one week following tumor cell injection to monitor the tumor growth. 
Mice were anesthetized with 2% isoflurane, inoculated intraperitoneal with 100 mg/kg D-
Luciferin potassium salt (BioVision) and imaged 10 minutes after injection. 
Bioluminescence was conducted using the IVIS 50 Lumina imaging station and regions 
of interest encompassing the intracranial area of signal/tumor, and the total 
Figure 8. Vaccination Schedule 
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photons/second/steradian/square cm (photons/s/sr/cm2) were defined using living image 
software. 
 
Cell Culture: GL261-Luc+ cells were grown in 25 ml of complete Dulbecco's 
Modification of Eagle's medium (DMEM), which consists of DMEM supplemented with 
10% fetal calf serum, 1% penicillin-streptomycin, and 1% nonessential amino acids in a 
T175 tissue culture flask incubating at 5% C02 and 37 °C. Prior to implantation the 
cultured cells are harvested by trypsinization, washed once in DMEM and resuspended in 
1X PBS at a concentration of 15 x 103 cells/ul. Murine CD11b cells were isolated from 
DAP12, DAP10 KO and wildtype mice by using CD11b MicroBeads (Miltenyi Biotec). 
Wildtype and knockout macrophages (raw 264.7) were cultured in Roswell Park 
Memorial Institute- (RPMI-)1640 medium supplemented with 10% fetal calf serum, 1% 
penicillin-streptomycin. 
 
Cytokine Secretion: Unless otherwise stated, all cells were treated at the same 
conditions for the cytokine secretion. A total of 1 × 106 cells was grown in 0. 500 ml in 
RPMI-1640 in a 48-well plate for 12 h, then pulsed with 10uM ligand P1, and incubated 
for an additional 48 h.  LPS (1uM) and non-pulsed cells were used as controls.  
Supernatant (50ul) were collected and analyzed for TNFa levels using cytometry bead 
array (Biosciences). Data was analyzed using Flowjo v10.  
 
Western analysis:  3 × 106 cells was grown in 0. 200 ml in RPMI-1640 in a 48-well 
plate for 12 hrs, then stimulated with 10uM ligand P1 for (0, 1, 3, 5, 7, 10, 15, 30, 60 
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min).  Following stimulation, cells were lysed on ice for 10 min in 200 ul of RIPA buffer 
(Thermo Fisher Scientific). Equal amounts of lysate (20 ug) were loaded, resolved by 
12% SDS-PAGE, transferred to Immobilon-P PVDF membrane (Millipore, Sigma), 
blocked with protein-Free T20 (TBS) blocking buffer (Thermo Fisher Scientific) and 
2.5% milk, and probed with rabbit specific phoshpo antibodies table 2. All antibodies 
were used at a dilution of 1:1,000. Horseradish peroxidase-conjugated donkey anti-rabbit 
IgG (HRP) (Jackson ImmunoResearch), and visualized with chemiluminescent substrate 
(Pierce Thermo Fisher Scientific). Non-pulsed cells were used as controls. Macrophages 
expressing two CD200ARs will be used to discriminate the DAP10 pathway mediated by 
CD200ARs. 
     
Density measurements:  Immunoblots were analyzed quantitatively by densitometry 
using an ibright fl1000 software (Thermo Fisher Scientific, Waltham, Massachusetts). 
Briefly, images were background-subtracted, and strips of the blot corresponding to each 
band were demarcated and analyzed for each time point/gel lane.  
 
RNA extraction and quantitative PCR analysis: Naïve CD11b were plated at a density 
of 1× 106 cells per 0.2 ml per well in 48-well in RPMI medium (described above) 1 d 
before the experiment and then stimulated with 10uM P1 and incubated for 1, 3, 5, 7, 15, 
30, 60 min or 6h, 12h, 18h, 24h. RNA was extracted  with Trizol according to the 
manufacturer’s instruction. cDNA was synthetized with QUANTA kit according to the 
manufacturer’s instruction. cDNA was analyzed by quantitative PCR with SYBR Green 
QPCR Mix on a QUANTA System. Primers were designed to amplify mRNA-specific 
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sequences corresponding the DAP10/12 molecules and, where possible, were placed on 
two separate exons spanning long intron in between. Gene expression was normalized to 
the expression of GAPDH or B-actin in the same sample and was calibrated to the 
expression in unstimulated wild-type samples. Inhibition assay. Naïve CD11b were 
treated as described above. Cells were pulsed with 10uM P38MAPK or 10nM Jak 








The goal of this dissertation was to elucidate the signaling pathway of the CD200 
paired receptors addressing a major knowledge gap of the immune system. The 
information described in these research projects reveals the signaling pathway of the 
CD200 immune checkpoint that leads to activation, rather than suppression, of immune 
cells that can be used to improve the response of GBM to immunotherapy. The central 
hypothesis is that synthetic ligands modulate CD200 activation receptors overriding the 
inhibitory effect mediated by CD200 binding to CD200R demonstrating that ligands can 
serve as therapeutic agents for checkpoint inhibitor-based immunotherapy.  
Towards testing our hypothesis, I developed and established CD200 receptor 
knockout macrophages from murine raw264.7 macrophages (Mfs). I used the 
CRISPR/Cas9 system to generate different Mf cell lines expressing different 
combinations of or a single CD200 receptor. The main achievements of this research 
are: i] the DAP10 and DAP12 pathways are the immune activation signaling of the 
CD200ARs to activate antigen-presenting cells and enhance the immune response; ii] 
CD200 activation receptors operate in complexes in that a combination of two activation 
receptors are needed to elicit an immune response; iii] the suggested immune mechanism 
of CD200 and its receptors is mediated by the DAP10/PI3K/VAV1-ERK1/2/cJUN 
pathway; and iv] ligation of CD200ARs enhances survival in our murine glioma model 
through DAP10 signaling.  
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Until this research was completed, to our knowledge, there was no known 
information about CD200ARs on immune cells. This knowledge gap blocked the 
complete understanding of how the CD200 protein, and its receptors regulate the immune 
system and specifically myeloid lineage cells. This dissertation reveals for the first time 
that both the DAP10 and DAP12 pathways are involved in immune signaling pathways 
of CD200ARs. Hence, these data fill this knowledge gap and can be considered as 
ground-breaking research. 
 
5.2 Overview of the Thesis 
The first chapter of this thesis provides the underlying problem in treating GBM that lays 
the groundwork for this research. First, it noted the clinical relevance of glioblastoma and 
the failure of the current standard care providing reasons why it is crucial to develop new 
treatments. It highlighted the mechanisms by which GBM suppresses an immune 
response that hinders the efficacy of current immunotherapy. Moreover, it stated the 
importance of CD200 as an understudied immune checkpoint protein and how crucial it 
is in regulating an immune response through its paired receptors. Due the ability of the 
CD200 protein to modulate an immune response, it may be considered as a novel 
immune checkpoint inhibitor for therapy of brain tumors like GBM, as well as, peripheral 
tumors. 
 Furthermore, it has pointed out that the CD200 protein and its receptors are 
crucial to maintaining homeostasis of the immune system.  The CD200 receptors are in 
the family of membrane-bound protein that can deliver inhibitory (through CD200R) or 
activating signals (through CD200ARs). It is known that the inhibitory signal is due to 
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specific binding of the native form of the CD200 protein to CD200R. CD200/CD200R 
binding induces activation of the canonical DOK pathway, recruits RasGAP and SHIP, 
and causes subsequent downstream inhibition of the RasMAPK pathways leading to 
suppression of immune cells. 
 One remarkable point is the lack of knowledge concerning CD200ARs. In spite of 
intensive investigation, ligands and immune signaling pathways had not been identified 
for CD200 activating receptors. There are two reports showing that two CD200 activation 
receptors, CD200AR4, and CD200AR3, coopt with the adaptor protein, DAP12, 
suggesting that these receptors would transmit strong activating signals. Nevertheless, the 
connection between recruitment of DAP12 and immune effector function had not been 
established.   
 Chapter 2 provides a review of published works of the Olin laboratory concerning 
establishing the utility of combining CD200-derived peptide with tumor lysate vaccines 
to treat GBM. The Olin laboratory has focused its attention on targeting an alternative 
immune checkpoint providing by CD200 immunosuppression. Our group is the first to 
promote two possible mechanisms of how CD200 immunosuppresses an antitumor 
response in GBM tumor microenvironment; i] CD200 is upregulated on the vascular 
endothelium of tumors leading to the immunosuppression of CD200R-bearing infiltrating 
leukocytes before they enter to the tumor microenvironment, and ii] CD200 is secreted 
from CNS tumors and interacts with the inhibitory CD200 receptor (CD200R) on 
immune cells in the tumor microenvironment and within the draining lymph nodes 
leading to suppression of anti-tumor response. We have demonstrated that the inhibitory 
effects of CD200 protein can be surmounted by selectively engaging CD200AR using 
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specific synthetic peptide ligands, CD200AR-Ls, that we identified using protein 
sequence analyses and structural data and have subsequently synthesized. 
 Finally, this laboratory has a great deal of experience in preclinical and clinical 
trials. We have demonstrated the efficacy of targeting the CD200ARs in immune 
activation, and survival in murine glioma models, where administration of the murine 
CD200-derivided ligand CD200AR-L in combination with tumor lysates significantly 
enhanced survival. Preclinical translational studies using a canine-specific CD200AR-L 
have resulted in a significant survival benefit in pet dogs with spontaneously developing 
high-grade glioma. In this study, 20 dogs were treated with canine-specific CD200AR-L 
and autologous tumor lysate vaccination following surgical resection of the gross tumor 
that provided a significant increase in median overall survival time compared to dogs 
treated similarly but without the CD200AR-L. These findings lead us to investigate 
further the activation effects of CD200ARs at the mechanistic level. 
 Chapter 3 describes the approach that I used to develop and test specific aim 1 
and its correlate hypothesis. First, it describes how I developed and validated different 
cell lines expressing one, two or three CD200ARs using the CRISPR/Cas 9 system. 
Furthermore, it describes the immunofluorescence/cell-binding assay using knockout 
CD200ARs M$s to validate the binding of CD200AR-L on the cell-surface of M$s. 
Third, several cell stimulation assays were performed to assess the biological function of 
CD200ARs. It describes the research design, cell lines, instrumentation, data collection 
and analyses that were used in the study. These data show that the ligand, CD200AR-L, 
binds to CD200AR2 and CD200AR3 and M$s expressing complexes of 
CD200AR2/AR3 induces the greatest amount of TNF#	production.   
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To summarize, the data in Chapter 3 provides evidence that CD200AR-L binds to 
CD200ARs cluster on the surface of antigen-presenting cells inducing immune activation 
demonstrated by cytokine secretion.  
Chapter 4 presents the strategy used to uncover the activation signaling of 
CD200ARs. It describes protein activation at both, the phospho-activation and gene 
expression, levels. Several cell stimulation assays were performed to conclude that 
optimal DAP10 and DAP12 pathway activation occurs at 3 and 5 minutes, respectively. 
The main role of DAP10 on the CD200ARs signaling was demonstrated when TNFa 
secretion was abolished on pulsed DAP10KO CD11b cells with CD200AR-L.. Moreover, 
it includes data from in vivo experiments that validate the relationship between DAP10 
and the CD200ARs. Overall, chapter 4 concludes that ligation between CD200AR-L and 
CD200ARs induces immune activation of APC through the DAP10 and DAP12 
pathways.  
 
5.3 Contributions of my Research 
5.3.1 Contribution of Specific Aim 1 
This research focused on the role of activation receptors (CD200ARs). This research 
shows that 
• CD200ARs form complexes to exert their biological functions. 
o Macrophages expressing CD200AR2&3 and 3&4 responded to peptide 
stimulation by the CD200AR-L to increase TNF-#	production. 
o Macrophages expressing a single CD200 receptor failed to induce TNF-# 
production. 
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o Macrophages expressing CD200R1, 2&3 or 1,3&4 failed to bind the 
fluorescent CD200AR-L and failed to elicit TNF#	production. 
o Macrophages expressing CD200AR2,3&4 bound fluorescent CD200AR-L 
but failed to produce TNF#. 
• CD200AR2 may be the most important receptor in activating an immune response 
o Macrophages expressing CD200R1, 2&4 bind to fluorescent CD200AR-L 
and induce TNF# production. 
 
Thus, these results show that innate cells, like macrophages, build distinct CD200AR 
complexes with different binding affinities to maintain homeostasis of the immune 
system. This is an important mechanism of how the immune system balances immune 
responses through receptor diversity. 
 
5.3.2 Contribution of Specific Aim 2. 
The main contributions to knowledge of the activation signaling of CD200ARs are: 
• DAP10 and DAP12 pathways are the immune signaling of CD200ARs. DAP10 
signaling induces cytolysis and cytokines secretion by natural killer cells when it 
associates with NKG2D. In our system, we found that monocytes (CD11b) 
activate DAP10/DAP12 pathways at different times after being pulsed with the 
ligand, CD200AR-L  
• The ligand CD200AR-L activates a DAP10 cascade. DAP10 has a cytoplasmic 
activation motif that is a predicted binding site for the SH2 domain of the P85 
subunit of PI 3-kinase (PI 3K). This work demonstrated that the CD200AR-L-
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stimulation induces increased gene expression of the DAP10 related-molecules 
including PI 3K. 
• DAP10/DAP12 form complexes. It has been demonstrated that DAP10 and 
DAP12 form heterodimers for signaling to induce activation of the immune 
system. These findings show that wildtype CD11b cells stimulated with 
CD200AR-L induce DAP10/DAP12 complex formation and no dimer formation 
was observed DAP10KO CD11b cells. 
• Knocking out the DAP10 and DAP12 pathways inhibits the CD200AR-L 
activation. Stimulated DAP10KO CD11b cells with CD200AR-L fail to produce 
TNF#. However, both DAP12KO and wildtype CD11b cells produce TNF#	
when	stimulated. Furthermore, in vivo experiments revealed that tumor-lysate 
and CD200AR-L treatment significantly increased tumor growth on DAP10KO 
mice-tumor-bearing. In contrast, wildtype and DAP12KO mice had significantly 
decreased tumor growth when treated with tumor lysate and CD200AR-L. These 
findings suggest that CD200AR-L induces DAP10 pathways, which is crucial to 
control of tumor growth. The reduced tumor growth in DAP12KO mice is likely 
due to the presence of the DAP10 pathway. Thus, we conclude that the 
CD200AR-L is crucial to activates DAP10 pathway on innate cells like 
macrophages -antigen-presenting cells- at the tumor microenvironment, so these 
cells take control of the tumor. 
Finally, this work suggests that the CD200AR-L stimulation induces that DAP10 
couples to the CD200ARs and stimulates downstream activation of 
phosphatidylinositol 3-kinase, Vav1, ERK1/2, and cJUN. These signals initiated by 
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CD200AR-L stimulation and CD200ARs/DAP10 activation are capable of inducing 
cytokine secretion in immune cells and controlling tumor growth in mice. Thus, these 
findings identify a previously unknown mechanism by which receptor complexes of 
CD200ARs that lack ITAM motifs can trigger macrophages activation. 
 
5.4 Future Directions 
Up to this time, little was known about the immunologically relevant expression 
of the CD200 receptors, except that CD200R is expressed in on some tumor cells. 
Further studies of the regulation of CD200ARs and their ligands may reveal the 
extent to which this system can provide protection against harmful conditions and 
whether any potentially detrimental effects are adequately counterbalanced by 
beneficial effects. 
Another consideration is since CD200 and its receptors have been shown to be 
important in myeloid cell activation, elucidating the immunological contexts of how 
CD200ARs may induce functional processes involved in killing microbes, 
presentation of antigen to CD4+ or CD8+ T cells, and inflammation or tissue repair 
will lead to a more comprehensive understanding of how myeloid cells maintain the 
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T cells. CD200R expression is particularly apparent in 
polarized Th2 cells [16], resulting in the expansion of 
regulatory T cells [17–19].
CD200 is expressed on tumors such as chronic lym-
phocytic leukemia [11], multiple myeloma [6], acute 
myeloid leukemia [20], melanoma [21], ovarian can-
cer [22], metastatic small cell carcinoma [23], GBM [4] 
and on the murine glioma GL261 (Figure 1A). In addi-
tion, tumor progression and poor patient outcome have 
been shown to correlate with the presence of soluble 
CD200 [24]. Wong et al. [24] reported that soluble 
CD200 levels in the plasma of chronic lymphocytic 
leukemia patients correlate with tumor burden and 
disease state. In our Phase I vaccine trial, we dem-
onstrated increasing levels of CD200 in the serum of 
our GBM and ependymoma immunotherapy patients 
upon tumor recurrence [4].
Absorbing CD200 out of tumor-derived 
vaccines enhances immunogenicity
Because CD200 is expressed on tumors, we hypoth-
esized that we are suppressing the immune system with 
the tumor-derived vaccines designed specifically to 
induce an anti-tumor immune response. To test our 
Figure 1.  Absorbing CD200 out of tumor-derived vaccines enhances immunogenicity.  (A) Human and mouse gliomas were analyzed 
by western analysis for CD200. (B & C) CD200 was absorbed out of murine GL261 tumor lysates and used to pulse (D) OT-1 splenocytes 
and (E) bone marrow derived dendritic cells with OVA as an immune stimulant with either wild-type GL261 or GL261 (CD200neg) 
tumor lysates. Error bars are ± SEM, asterisk represent a statistical significance *p < 0.05, **p = 0.005 or ***p = 0.0005 determined by 
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hypothesis, we depleted CD200 from our tumor lysates 
using immunoprecipitation (Figure 1B & C). OT-I sple-
nocytes were pulsed with ovalbumin (OVA) + GL261 
tumor lysate (GL261) or GL261 depleted of CD200 
(GL261 (CD200neg)). GL261 significantly suppressed 
the ability of OVA to induce an immune response (p = 
0.009), which was reverted by depleting CD200 from 
the vaccine (p = 0.003) (Figure 1D). Because CD200 
acts on antigen-presenting cells [19], we repeated this 
experiment with bone marrow-derived dendritic cells 
(DCs). Our experiments recapitulated the findings 
in Figure 1D that, compared with OVA alone, tumor 
lysates containing CD200 inhibited IFN-γ (p = 0.001) 
and IL-2 (p = 0.005) production, a result which was 
reversed by depleting CD200 (p = 0.001) (IFN-γ), p = 
0.001 (Figure 1E) and (IL-2) (Figure 1F).
CD200 inhibitor blocks immune suppression 
from tumor-derived vaccines
Targeting receptor–ligand interactions has become 
increasingly important, as indicated by CD200/
CD200 receptor (CD200R) in leukemia cells and 
CD47/SIRP in many cancers cells [11,25–27]. We devel-
oped a peptide inhibitor targeting the CD200R iso-
form activation receptors [4]. Purified CD11b cells from 
wild-type mice were pulsed with tumor lysate contain-
Figure 2.  CD200 peptide inhibitor blocks the suppressive properties of CD200. (A–F) CD11b cells were isolated 
from C57BL/6 wild-type mice were pulsed with tumor lysates derived from wild-type Gl261 cells +/- the CD200 
peptide inhibitor. Supernatants were analyzed for chemokine and cytokine secretion. Error bars are ± SEM, 
asterisk represent a statistical significance *p < 0.05 or **p = 0.005 determined by unpaired t-test. Experiments are 
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ing CD200, with or without the CD200 inhibitor. 
In these experiments, with the exception of TNF-α 
and IL1α (p = 0.07 and p = 0.12 respectively), tumor 
lysates alone elicited a statistically significant cytokine 
response (p = 0.003 (GM-CSF), p = 0.012 (IL6), p = 
0.02 (CXCL9) and p = 0.006 (RANTES) compared 
with no pulse controls. The CD200 inhibitor treat-
ment group achieved a statistically significant enhanced 
immune response p = 0.004 (TNF-α), p = 0.001 
(GM-CSF), p = 0.033 (IL1α), p = 0.015 (CXCL9), p = 
0.001 (IL6) and p = 0.013 (RANTES) compared with 
no pulse control and p = 0.015 (GM-CSF), p = 0.023 
(IL1α), p = 0.015 (CXCL9), p = 0.015 (IL6) and p = 
0.046 (RANTES) compared with tumor lysate groups 
alone (Figures 2A–F). We observed enhanced secretion 
of TNF-α when adding the CD200 inhibitor to tumor 
lysates, however, these results failed to reach statistical 
significance (p =  0.069).
CD200 inhibitor enhances an antigen-
specific response
To generate a tumor-specific immune response, CD8 
T cells undergo priming by DC, the antigen-present-
ing cell most efficient at initiating potent CD8+ T-cell 
responses [28,29]. Currently, the efficacy of ex vivo 
derived DC immunotherapy is not well established 
for human cancers [30–33]. The limited success of these 
immunotherapies has been attributed to a variety of 
factors, including the preparation and administration 
Figure 3.  CD200 inhibitor enhances an antigen-specific 
response. (A & B) Bone marrow-derived dendritic 
cells from wild-type C57Bl/6 or CD200R KO mice were 
pulsed with OVA, OVA + CD200, OVA + CD200 + 
CD200 inhibitor or OVA + CD200 + scrambled inhibitor. 
Following 24 h incubation, cells were washed, and 
purified  OT-I CD8 T cells were added. Following 48 h 
incubation, supernatants were analyzed for IFN-γ 
production. Experiments are representative of three 
separate experiments. Error bars are ± SEM, asterisks 
represent a statistical significance *p < 0.05, **p = 

































































Figure 4.  CD200 inhibitor modifies gene expression. 
Purified CD11b cells isolated from wild-type C5Bl/6 mice 
were pulsed with CD200 inhibitor. RNA was isolated 
and analyzed by NanoString for 575 immune-related 
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of the vaccine, the disease stage of the participants in 
experimental trials, or the heterogeneous nature of 
most tumors. We suggest the failure to elicit an anti-
tumor response is due to CD200 in tumor-derived 
v accines used to activate DC.
To test this, bone marrow-derived DC from wild-
type mice were pulsed with OVA + CD200 with or 
without the CD200 inhibitor. Following 24 h incu-
bation, cells were washed to remove any free inhibi-
tor, then incubated with purified OT-I cells. As previ-
ously demonstrated in vivo [4], the CD200 inhibitor 
blocked the suppressive effects of CD200, revert-
ing to an antigen-specific OVA immune response 
(Figure 3A). OVA significantly enhanced an IFN-γ 
response (p = 0.007), which was suppressed with the 
addition of CD200 (p = 0.009). The addition of the 
CD200 inhibitor overpowered the suppressive prop-
erties of the CD200 protein, significantly enhancing 
an immune response (p = 0.003), as compared with 
using OVA alone. Interestingly, in these experiments, 
we observed that cells pulsed with CD200 inhibitor 
+ OVA significantly enhanced the immune response 
(p = 0.001) (Figure 3B) compared with OVA treated 
cells. These studies led us to hypothesize that the 
CD200 inhibitor activates antigen-presenting cells.
CD200 inhibitor modifies gene expression
To test our hypothesis that the CD200 inhibitor acti-
vates antigen-presenting cells, CD11b cells from wild-
type splenocytes were pulsed with CD200 protein, 
CD200 inhibitor or a combination of CD200 protein 
+ CD200 inhibitor and analyzed by NanoString for 
575 immune-related genes. All treatment groups were 
normalized to no pulse controls. In these experiments, 
194 immune-related genes had a ± 1.5-fold change 
following pulsing with the CD200 inhibitor alone 
(Figure 4A–C).
When we compared all three treatment groups, 
we observed that 98 genes within the CD200 pro-
tein group had an opposite response compared with 
genes within the CD200 inhibitor or CD200 protein 
+ CD200 inhibitor treatment groups (Figure 5A & B). 
These experiments demonstrated that the CD200 
inhibitor reversed the inhibitory signaling induced by 
the CD200 protein.
To determine if the CD200 inhibitor activated func-
tional responses, DCs were pulsed with the CD200 
inhibitor alone. These experiments revealed that the 
CD200 inhibitor activated DCs, statistically enhanc-
ing the production of IL-2, TNF-α, IL-1α, IL-6, GM-
CSF and IL-1β (p = 0.01, p = 0.02, p = 0.04, p = 0.001, 
Figure 5.  CD200 inhibitor reverses CD200 protein inhibitory signals. Purified CD11b cells isolated from wild-type 
C5Bl/6 mice were pulsed with a CD200 protein, CD200 inhibitor or a combination of CD200 protein and CD200 
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tein group had an opposite response compared with 
genes within the CD200 inhibitor or CD200 protein 
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the CD200 protein.
To determine if the CD200 inhibitor activated func-
tional responses, DCs were pulsed with the CD200 
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with the CD200 inhibitor 1 h prior to revaccination 
with tumor lysates + CD200 inhibitor (Figure 7A–C).
6 h following revaccination, skin at the vaccine site 
was harvested and analyzed for leukocyte infiltration. 
No significant leukocyte infiltration was observed in 
saline vaccinated controls or in CD200R KO mice vac-
cinated with tumor lysates + CD200 inhibitor (data not 
shown). To quantify our results, vascular leukocytes 
from eight layers of tissue were counted (Figure 7D). 
These experiments demonstrated enhanced leukocyte 
infiltration into the vaccine site with as little as 1-h pre-
vaccination with the CD200 inhibitor (p = 0.001; 1 h 
and p = 0.001 24 h) (Figure 7D). Moreover, knocking 
out the CD200 receptor failed to enhance leukocyte 
infiltration (p = 0.087).
These experiments demonstrated that while we 
were capable of eliciting an immune response using 
tumor-derived vaccines, the response failed to recruit 
antigen-presenting cells to the site of vaccination for 
antigen uptake. We next wanted to see how removing 
CD200 from tumor lysate vaccines influenced leu-
kocyte infiltration. In these experiments, non-tumor-
bearing wild-type mice were vaccinated with tumor 
lysate or tumor lysate void of CD200. 24 h later, mice 
Figure 7.  CD200 inhibitor enhances leukocyte trafficking into the vaccine site. Non-tumor-bearing C57Bl/6 or 
CD200R knockout mice were vaccinated with tumor lysates or CD200 inhibitor, either 1 or 24 h later, mice were 
revaccinated with (A) tumor lysates + CpG or (B) tumor lysates, CD200 inhibitor + CpG (1 h revaccination). (C) tumor 
lysates, CD200 inhibitor + CpG (24-h revaccination). 6 h later, skin from the vaccine sites was harvested and analyzed 
by H&E staining. (D) Leukocytes within blood vessels in eight separate skin levels were counted. (E) In separate 
experiments, mice were vaccinated with wild-type GL261 lysates or GL261 lysates void of CD200. 24 h later, mice 
were revaccinated with either wild-type GL261 lysates or GL261 lysates void of CD200 + CpG. 6 h later, skin was 
harvested and leukocytes within blood vessels in eight separate skin levels were counted. Error bars are ± SEM, 
asterisks represent a statistical significance *p < 0.05, **p = 0.005 and ***p = 0.0005 determined by unpaired t-test.
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were revaccinated with tumor lysate + CpG-ODN or 
tumor lysate void of CD200 + CpG-ODN, respec-
tively (Figure 7E). As seen in the above experiments, 
we observed a significant infiltration of leukocytes into 
the site of vaccination (p = 0.004), however, removal 
of CD200 profoundly enhanced leukocyte infiltration 
(p = 0.0001) (Figure 7E).
Figure 8.  CD200 inhibitor enhances an antitumor 
response. (A) Purified CD11b cells from wild-type 
C57Bl/6 cells were pulsed with OVA ± CD200 inhibitor. 
Forty-eight hours later, cells were analyzed for CD80/86 
and MHC-II expression. (B) Tumor-bearing wild-type 
(solid symbols) or CD200 receptor knockout (CD200R 
KO) (open symbols) mice were vaccinated in the back 
of the neck with saline (black lines), wild-type GL261 
tumor lysates (red lines), tumor lysates + scrambled 
CD200 inhibitor (blue lines) or tumor lysate + CD200 
inhibitor (green lines). 20 days post vaccination, 
lymphocytes from cervical lymph nodes were 
harvested, incubated for 6 h with wild-type GL261 cells 
and analyzed for cytolytic activity. Asterisks represent 
















Figure 9.  CD200 is upregulated in vascular endothelial 
cells. Tissues isolated from (A) normal human CNS or 
(B) glioblastoma multiforme (GBM) were analyzed 
for CD200 expression. (C) Vascular endothelial cells 
from normal tissue and GBM (D) breast tumor and (E) 
melanoma cells were analyzed for CD200 expression. 
Human endothelial cells were expanded on the bottom 
of a trans-well plate. GBM cells were placed on the 
top of the plates and incubated for 48 h. HUVAC were 
washed and analyzed by (F) western analysis and (G) 
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et al. [35]. Mice were vaccinated with tumor lysates 
with or without the CD200 inhibitor (Figure 8B). 
Scrambled inhibitor was used as a control. Twenty 
days post inoculation, lymphocytes from draining 
cervical lymph nodes were harvested and incubated 
with GL261 cells to initiate a tumoricidal response. 
Two-way ANOVA revealed a statistically significant 
enhancement of an anti-tumor response by lym-
phocytes with the addition of the CD200 inhibitor 
(p = 0.001) (Figure 8B).
Individual analysis by Student’s t-test revealed that 
tumor lysates in both wild-type and CD200R knock-
out mice with significantly enhanced anti-tumor 
responses (p = 0.001 and p = 0.001) at effector:target 
cell ratios of 25:1 and 50:1, respectively, as compared 
with the saline treatment group. In addition, the 
CD200 inhibitor group significantly enhanced anti-
tumor responses (p = 0.001, p = 0.001 and p = 0.001) 
at effector:target cell ratios of 5:1, 25:1 and 50:1, 
respectively, as compared with the saline treatment 
group. In wild-type mice, the CD200 inhibitor treat-
ment group exhibited significantly enhanced antitu-
mor responses at effector:target cell ratios of 5:1, 25:1 
and 50:1 (p = 0.0001, p = 0.026 and p = 0.003, respec-
tively) as compared with the tumor lysate treatment 
group. In addition, there was a significantly enhanced 
anti-tumor response between CD200 inhibitor and 
CD200 scrambled inhibitor control treatment groups 
in wild-type mice at effector:target cell ratios of 
5:1, 25:1 and 50:1 (p = 0.001, p = 0.0066 and p = 
0.0018, respectively). We also observed significantly 
enhanced anti-tumor responses at effector:target cell 
ratios 5:1, 25:1 and 50:1 (p = 0.006, p = 0.016 and p = 
0.006, respectively) between wild-type and CD200R 
KO mice in the CD200 inhibitor treatment group. 
No significant differences were observed between 
wild-type and CD200R KO mice treated with tumor 
lysates or the scrambled inhibitor. These experiments 
demonstrated the ability of our inhibitor to enhance 
an anti-tumor response when used in conjunction 
with a tumor-derived vaccines.
CD200 is upregulated on endothelial cells
Inhibiting CD200/CD200R interactions has been 
suggested as a method to enhance immunother-
apy [11,36–39]. A clinical trial sponsored by Alexin 
Pharmaceuticals (NCT00648739) developed a 
monoclonal anti-CD200 (ALXN6000) to block 
tumor-derived CD200 expressed on B-cell chronic 
lymphocytic leukemia and multiple myeloma cells 
from interacting with CD200R+ lymphocytes (clini-
calTrials.gov) [39]. No results have been posted in 
clinicaltrials.gov. We do not anticipate that this 
method will be a very efficacious therapy. Twito et 
al. [40] has demonstrated that ‘A Disintegrin And 
Metalloprotease’ enzyme (ADAM28) sheds CD200 
from B-cell chronic lymphocytic leukemia [40], 
which would invalidate the use of an antibody to 
block tumor-driven CD200–CD200R interactions. 
Our preliminary data correlate with Twito’s find-
ings. We reported high transcription levels of CD200 
in GBM [4], however, staining for CD200 protein 
revealed that, in contrast to normal CNS, GBM have 
low CD200 expression (Figure 9A & B) potentially due 
to secretion.
To validate CD200 protein expression on GBMs, 
human GBM were analyzed for CD200 expression 
by western analysis. In contrast to normal CNS tis-
sue, there was low expression of CD200 on the 
tumors. However, closer examination revealed that 
GBMs increase expression of CD200 on endothe-
lial cells within the blood–brain barrier (Figure 9C). 
The same CD200 expression was seen in the vascu-
lature of human breast carcinoma (Figure 9D) and 
melanoma (Figure 9E). To determine the ability of 
GBM to upregulate CD200, human endothelial cells 
(HUVAC) were placed on the bottom of a trans-well 
plate and human GBM was placed on the top. Fol-
lowing 72-h incubation, HUVAC cells were harvested 
and analyzed by western immunoblot (Figure 9F) and 
RT-PCR (Figure 9G) for CD200. These experiments 
demonstrated that GBM induces CD200+ e ndothelial 
cells.
Conclusion
CD200 has been well described as immunosup-
pressive, making it a logical target for immunother-
apy [4,8,11]. We have been extensively interrogating 
the multiple mechanisms by which CD200 inhibits 
the development of an antitumor response. We sug-
gest that the CD200 in the tumor-derived vaccines 
and the CD200 protein secreted from the tumor 
micro-environment will inhibit the ability of anti-
gen-presenting cells to mount an antitumor response 
(Figure 10A & B). We also argue that our CD200 pep-
tide inhibitor, through the activation of a CD200 iso-
form receptor, reverses CD200-induced suppression 
(Figure 10C).
Our model is supported by studies reporting that 
CD200/CD200R interactions have been character-
ized as inhibitory receptors [26,41]. CD200R contains 
tyrosine motifs which signal through the recruitment 
of DOC2 to distinguish the CD200R from almost all 
other inhibitory receptors that have immunoreceptor 
tyrosine-based inhibition motifs [42]. However, addi-
tional CD200R-like proteins have recently been iden-
tified in mice and humans [13]. Four separate CD200 
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CD200R2, CD200R3 and CD200R4 [41,43]. These 
receptors are predicted to be associated with DNAX 
activating protein, (DAP)12, known to potenti-
ate and attenuate activation of leukocytes [13,44]. 
Although the CD200R isoforms have not been well 
characterized, Gorczynski et al. reported that specific 
peptide sequences within the CD200 protein act as 
antagonists. Gorczynski hypothesizes that these pep-
tide sequences bind to one of the CD200R isoforms 
that normally contribute an activation signal [45].
Our data correlate with Gorczynski’s hypothesis. 
We suggest that our CD200 inhibitor is targeting 
one of the activation isoforms of the CD200 recep-
tor. However, CD200 has multiple mechanisms 
of inducing immune suppression. Following close 
examination of CD200 immunohistochemistry, we 
have demonstrated that CD200 is upregulated on 
vascular endothelial cells (Figure 9C). CD200+ endo-
thelial cells appear to be tumor-specific because the 
surrounding CNS does not express CD200 in the 
blood–brain barrier vasculature (data not shown). 
This is an important discovery because others 
have reported that tumor-CD200 expression dif-
ferentiates CD4+CD200R+ cells into a suppressor 
T-regulatory population (reviewed in [46]) [17]. We 
suggest that CD200R-bearing leukocytes will inter-
act with CD200+ endothelial cells to differentiate 
CD4+CD200R+ to regulatory T cells, leading to 
the development of an immunosuppressive tumor 
e nvironment (Figure 10C).
Future perspective
Breaking CD200/CD200R interactions intensifies 
the success of antitumor therapy (reviewed in [46]). 
We developed a 13 amino acid CD200 peptide 
inhibitor that, given with tumor lysate, significantly 
enhances immunogenicity in our glioma model, as 
well as our breast carcinoma model [4]. We are now 
focusing our efforts on a mechanism to overcome the 
suppressive CD200+ endothelial cells (Figure 9C). We 
are developing a monoclonal anti-CD200R specific 
for the same epitope as our CD200 inhibitor, which 
we hope will block the differentiation of immune sup-
pressor cells. We hypothesize that, following T-cell 
activation, systemic inoculation of the anti-CD200R 
will bind the CD200R on CD200R+ leukocytes. Our 
preliminary data suggest that blocking CD200R will 
allow CD200R leukocytes to enter the tumor micro-
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Tumor-derived CD200 in vaccines inhibits an anti-tumor response
s  Tumor-derived vaccines are widely used for solid tumor immunotherapy.
s  Tumor-derived vaccines contain immunosuppressive proteins.
s  CD200/CD200R interaction is an immune checkpoint manipulated by tumors and suppressing an immune 
response, enhancing immune escape.
CD200 inhibitor blocks immune suppression from tumor-derived vaccines
s  CD200 peptide inhibitor blocks the suppressive effects of CD200 in tumor-derived vaccines.
s  CD200 inhibitor enhances leukocyte infiltration into the vaccination site.
CD200 inhibitor enhances immunogenicity
s  Tumor lysate combined with the CD200 inhibitor significantly enhances the development of an anti-tumor 
response.
CD200 inhibitor activates antigen-presenting cells
s  CD200 inhibitor acts as an agonist activating antigen-presenting cells, enhancing immune activation.
CD200 is upregulated on vascular endothelial blood vessel cells
s  Glioblastoma multiforme, breast tumors and melanoma upregulate CD200 on endothelial cells surrounding 
tumors, enhancing immune escape.
Conclusion
s  CD200 is a major limitation for the development of an anti-tumor response.
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ABSTRACT
◥
Purpose: Advances in immunotherapy have revolutionized care
for some patients with cancer. However, current checkpoint inhi-
bitors are associated with significant toxicity and yield poor
responses for patients with central nervous system tumors, calling
into question whether cancer immunotherapy can be applied to
glioblastoma multiforme. We determined that targeting the CD200
activation receptors (CD200AR) of the CD200 checkpoint with a
peptide inhibitor (CD200AR-L) overcomes tumor-induced immu-
nosuppression. We have shown the clinical efficacy of the
CD200AR-L in a trial in companion dogs with spontaneous
high-grade glioma. Addition of the peptide to autologous tumor
lysate vaccines significantly increased themedian overall survival to
12.7 months relative to tumor lysate vaccines alone, 6.36 months.
Experimental Design: This study was developed to elucidate the
mechanism of the CD200ARs and develop a humanized peptide
inhibitor. We developed macrophage cell lines with each of four
CD200ARs knocked out to determine their binding specificity and
functional response. Using proteomics, we developed humanized
CD200AR-L to explore their effects on cytokine/chemokine
response, dendritic cell maturation and CMV pp65 antigen
response in human CD14þ cells. GMP-grade peptide was further
validated for activity.
Results: We demonstrated that the CD200AR-L specifically
targets a CD200AR complex.Moreover, we developed and validated
a humanized CD200AR-L for inducing chemokine response, stim-
ulating immature dendritic cell differentiation and significantly
enhanced an antigen-specific response, and determined that the
use of the CD200AR-L downregulated the expression of CD200
inhibitory and PD-1 receptors.
Conclusions: These results support consideration of a
CD200AR-L as a novel platform for immunotherapy against mul-
tiple cancers including glioblastoma multiforme.
Introduction
The discovery of immune checkpoints and their inhibition (“check-
point blockade”) is a recently developed modality for the treatment of
cancer that has truly revolutionized care for some patients (1, 2).
Current FDA-approved checkpoint inhibitors are mAbs that can
extend survival in patients with selected solid tumors such as mela-
noma. However, many solid tumors respond poorly to checkpoint
inhibitors. This includes glioblastoma multiforme (GBM; ref. 3), an
incurable primary central nervous system (CNS) tumor with amedian
overall survival of 14.6 months with the current standard of care (4, 5).
Combinations of inhibitors to target multiple immune checkpoint
pathways have been employed in an effort to significantly enhance
survival. Unfortunately, these combinations can cause severe immune-
related adverse events, often leading to treatment discontinuation or
morbidity and mortality (6–9).
TheCD200 immune checkpoint causes suppression of the secretion of
proinflammatory cytokines, including IL2 and IFNg (10, 11), and
increases production of myeloid-derived suppressor cells (12) and T
regulatory cells (12–14) resulting in compromised antitumor activity.
Previously, we discovered the following mechanisms employed by the
CD200 protein for immunosuppression: (i) it is upregulated in GBM-
associated endothelial cells creating an immunologic barrier around the
tumormicroenvironment (10); and (ii) it is shed fromtumors (12, 15) and
interactswith theCD200 inhibitory receptor (CD200R1)on immune cells
both in the tumormicroenvironment anddraining lymph nodes (10, 15).
Our research focuses on the development of a therapeutic agent that
targets the CD200 immune checkpoint regulatory system, which is
known to modulate an immune response through CD200R1 (10, 12).
However, in addition to the inhibitory CD200R1, there is a series of
activation receptors (CD200AR2, 3, 4, and 5) in mice (16). By using
specific synthetic peptide ligands (CD200AR-L) that we identified
through protein sequencing and structural analyses of CD200 (10), we
developed a peptide-based strategy to engage these activation receptors
on immune cells (10) and demonstrated that the inhibitory effects of
CD200 protein can be surmounted by selectively engaging
CD200ARs (11, 17). This was accomplished using specific
CD200AR-L that we identified through protein sequencing and
structural analyses of the native CD200 protein (10). The ability to
overpower the suppressive effects of CD200 is lost when using a
scrambled CD200AR-L or CD200ARKO mice, demonstrating that
these peptides mimic active sites within the CD200 protein to mod-
ulate CD200AR activity resulting in immune stimulation (10, 12).
We tested the efficacy of the CD200AR-L in companion dogs with
spontaneous high-grade glioma using a canine-specific peptide (18). In
this study, intradermal injections of the canine CD200AR-L prior to
and during administration of autologous tumor lysate vaccines
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significantly enhanced the efficacy of this immunotherapeutic modal-
ity, doubling the median overall survival time compared with dogs
receiving tumor lysate vaccines alone (18). We found the therapeutic
effect of CD200AR-L compelling enough to translate these findings
into the human clinical setting. Herein, we describe the binding of
CD200AR-L to specific CD200ARs on antigen-presenting cells (APC)
resulting in immune activation. We also describe the development of
specific human CD200AR-Ls that enhance the ability of human APCs
to initiate an antigen-specific response.
Materials and Methods
Transfection
Cells from the macrophage cell line, Raw 264.7, were incubated in
RPMI1640 supplemented with 10% FCS and 1% penicillin/strepto-
mycin at 37!C until confluent. Upon confluency, transfection was
performed using the Neon electroporation system (Thermo Fisher
Scientific). A total of 5 " 104 cells were harvested and incubated in
10-mL Neon Buffer R with 1 mL (1 mg/mL) of Clean-Cap Cas9 mRNA
(TriLink Biotechnologies) and 1-mL (100 pmol/mL) CRISPR evolution
sgRNA Synthego (Synthego) for 2minutes. Following incubation, cells
were placed in a Neo electroporator at 1,720 pulse voltage, 10 pulse
width, and two pulse numbers. Two days after transfection, cells were
analyzed by PCR to validate the deletion of each CD200AR.
Immunofluorescence cell-binding assay
A total of 5 " 104 macrophages were grown in a Lab-Tek II 8
chamber slide in 200-mL RPMI containing 10% calf serum and 1%
penicillin/streptomycin. At approximately 70% confluency, cells were
washed twice with 1" PBS, pulsed with 10 mmol/L biotinylated
CD200AR-L for an hour, fixed in 4%paraformaldehyde for 20minutes
at room temperature, then incubatedwith streptavidinAlexa Fluor 568
conjugate (Thermo Fisher Scientific) for 1 hour, washed with 1" PBS,
and stainedwith 1-mgDAPI. Imagingwas performedusing an Inverted
Ti-E Deconvolution Microscope System (Nikon Instruments Inc.).
Peptide synthesis
Human peptides (P1: IVTWQKKKAVSPENM, P2: NITLEDEGCY-
MCLFN, P3: VTFSENHGVVIQPAY and P4: CLFNTFGFGKISGTA)
were synthesized (Thermo Fisher Scientific; Fig. 2A). The purity of the
peptides was >95% and each peptide was modified by N-terminal
acetylation and C-terminal amidation to enhance their stability.
Cytokine measurements
A total of 5 " 105 humanCD14þ cells were isolated from peripheral
blood mononuclear cells (PBMC) using anti-CD14 beads (BD Bios-
ciences) with a typical yield of $ 70% recovery and $ 90% purity. Cells
were pulsed with 2 mmol/L of each CD200AR-L, P1, 2, 3, or 4 and
incubated for 48 hours. The supernatants were then analyzed by bead
array for cytokine production (BD Biosciences).
Dendritic cell differentiation
CD14þ cells were purified from cytomegalovirus positive (CMVþ )
HLA-A2þ lymphocyte packs (American Red Cross) as described
above. Approximately 8 " 108 cells were cultured in polystyrene tissue
culture flasks at 37!C in 5%CO2. GM-CSF (25 ng/mL) and IL4 (40 ng/
mL) were added on days 3 and 5 to derive immature dendritic cells
(iDC).
Cytomegalovirus assay
iDCs (5 " 105) were pulsed with 10-mg cytomegalovirus (CMV)
antigen peptide pp65495–503 (NLVPMVATV) and cultured as
described above. iDCs were washed three times and coincubated with
CD8þ T cells from CMVþ donors (5 " 105). PBMCs from CMV%
donors were used as a negative control. Supernatants were collected
after 48 hours of incubation and analyzed for IFNg production by
cytometric bead array (BD Biosciences).
NanoString gene expression analysis
Total RNA from CD14þ cells was sent to New Zealand Genomics
Limited to measure the expression of genes that are differentially
expressed during inflammation (nCounter GX, NanoString Tech-
nologies). Briefly, total RNA was extracted from CD14þ cells
(MagJET RNA kit, Thermo Fisher Scientific) using the protocol
adapted for tissue (KingFisher Duo machine, Thermo Fisher Sci-
entific). RNA samples were then quantified (Qubit 2.0 fluorometer,
Thermo Fisher Scientific) and subjected to RNA integrity analysis
(2100 Bioanalyzer, Agilent Technologies). Probes for the genes
encoding CD44 (NM_001001392.1), NANOG (NM_024865.2),
OCT4 (NM_002701.4), STAT3 (NM_139276.2), and the house-
keeping genes glucuronidase beta (GUSB; NM_000181.1), clathrin
heavy chain (CLTC; NM_4859.2), and hypoxanthine phosphori-
bosyltransferase 1 (NM_000194.1) were designed and manufac-
tured by NanoString Technologies.
Expression data obtained with NanoString GX were analyzed using
nSolver Analysis Software 3.0 (nanostring.com/products/nSolver)
using default settings and normalized to housekeeping genes. nSolver
performed cluster analysis and generated heatmaps using Java Tree-
view Version: 1.1.6r4. Pathway analysis was performed using Path-
Cards Pathway Unification Database (pathcards.genecards.org;
ref. 19). Student t tests were used to determine significant differences
among groups (P < 0.05).
Results
Murine CD200AR-L binds CD200AR2&3 and CD200AR3&4 to
activate APCs
The CD200 checkpoint modulates immune responses through
paired receptors; an inhibitory receptor (CD200R1; ref. 20) and several
activation receptors (CD200ARs). Two CD200ARs are expressed
on human immune cells and four on murine cells (CD200AR2–5;
Translational Relevance
This report evaluates the ability tomodulate the CD200 immune
checkpoint by employing synthetic peptides directed as ligands
to its paired immune activation receptor. We previously
reported the presence of CD200 in the sera and tumor vascu-
lature of patients with glioblastoma multiforme (GBM). We
have also shown that a canine CD200AR-L extends the lives of
companion dogs with high-grade glioma. The data we present
here show that the human CD200AR-L directed to the CD200
activation receptor on CD14þ cells activates immune upregula-
tion through induction of cytokine response and dendritic cell
differentiation. In addition, hCD200AR-L downregulates the
inhibitory CD200 and PD-1 receptors. These findings provide
a basis to evaluate hCD200AR-L as a novel immune therapy for
patients with GBM. Downregulation of PD-1 suggests that
hCD200ARL may also obviate the need for PD1- and PD-L1–
directed therapies for GBM and other malignancies.
Targeting CD200 Checkpoint: A New Approach for Immunotherapy
AACRJournals.org Clin Cancer Res; 26(1) January 1, 2020 233
on March 11, 2020. © 2020 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from 







refs. 11, 21). Although interactions between CD200 and the inhibitory
receptor have been characterized, the natural ligands for the activation
receptors and themolecular signaling that results from ligation remain
unknown. We have demonstrated that targeting CD200ARs may
represent a promising approach for immunotherapy by enhancing
an antiglioma response in induced murine and spontaneous canine
models with the addition of CD200AR-L to autologous tumor lysate
vaccination. However, wewished to establish a better understanding of
themechanisms involved in targeting CD200ARs before translation to
patients with human glioblastoma. To achieve this, a murine macro-
phage cell line was pulsed with a fluorescently labeled murine
CD200AR-L (Fig. 1A) to validate binding. Using CRISPR, we created
macrophage cell lines expressing single or combinations of
CD200ARs. To achieve this, macrophage cells first had either
CD200R1 or one of the CD200ARs knocked out (Supplementary
Fig. S1A). These single knockout cell lines were then used to develop
dual receptor knockout cell lines, which then had further receptor
knockouts to create cell lines expressing a single CD200 receptor
(Supplementary Figs. S1B–S1F). Cells were validated by PCR to
validate gene removal using wild-type cells as a positive control. All
A Wild-type B CD200AR2KO C CD200AR3KO D CD200AR4KO E CD200AR3&4
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CD200AR-L binds to CD200AR complexes. Wild-type (A), CD200AR2KO (B), CD200AR3KO (C), CD200AR4KO (D), CD200AR3&4 expressing (E), CD200AR2&3
expressing (F), and CD200AR2&4–expressingmacrophages (G) were pulsed with fluorescently labeled CD200AR-L and assessed bymicroscopy. Cells were pulsed
with the unlabeled CD200AR-L, incubated for 48 hours, and supernatants were analyzed for alterations in IL6 (H), IL12 (I), TNFa (J), and MCP-1 production (K).
Nonpulsed cells with the same receptors were used as controls. Error bars, SD (n¼ 3/group; " , P < 0.05; "" , P < 0.005; """, P < 0.0005; """" , P < 0.00005 by t test).
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receptor knockouts were sequenced to validate gene removal (Sup-
plementary Figs. S1A, S1G, and S1H). Cells with receptor 1, 3, and 4
knockout were validated by flow cytometry; however, there is no
commercially available anti-CD200AR2 antibody. Relative to wild-
type cells, reduced peptide binding was seen on CD200AR2KO and
CD200AR3KO and no peptide binding was observed on
CD200AR4KO cells. However, we subsequently demonstrated strong
peptide binding on cells expressing CD200AR2&3, CD200AR3&4,
and CD200AR2&4 (Fig. 1A–G).
We next wanted to determine the functional effects of ligand
binding to the different CD200ARs. Cell lines were pulsed with the
murine CD200AR-L and supernatants were analyzed for cytokine
production. These experiments correlated with the binding experi-
ments in that the pulsed cells expressing CD200ARs 2&3 and 2&4 had
a significant increase in IL6 and TNFa production, and those expres-
sing CD200AR2&3 had a significant increase in IL12 and MCP-1
compared with the unpulsed controls (Fig. 1H–K). These experiments
demonstrated that the CD200AR-L targets activating receptor com-
plexes, specifically CD200AR2&3 and CD200AR3&4, to activate
APCs.
Design and identification of inhibitory peptides against
CD200AR-L
Because we were now confident that we were targeting activation
receptors with the peptide ligands, we sought to develop human-
specific CD200AR-Ls for clinical use. Previous analysis of regions of
CD200 that interact with CD200ARs revealed four regions with
significant homology among the human, canine, and murine proteins
(Fig. 2A). Four CD200AR-L peptides termed P1–4 were generated. To
determine whether these peptides activated human APCs as we
previously observed for the murine CD200-mimic peptides (10),
purified human CD14þ cells were pulsed with each of the four
CD200AR-L peptides and supernatants were analyzed for immunos-
timulatory cytokines. We observed a significant increase in IL1b (P¼
0.0126, P¼ 0.0364, P¼ 0.0022, P¼ 0.008) and TNFa (P¼ 0.0146, P¼
0.0007, P¼ 0.0002, and P¼ 0.0082) in CD14þ cells pulsed with P1, P2,
P3, or P4, respectively, compared with unpulsed controls (Fig. 2B and
C). To determine an antigen-specific response, we used a CMVmodel
in which T cells fromCMVþ donors are primedwith the CMV antigen
pp65. Pulsing iDCs with CMV antigen pp65 and each of the
CD200AR-L peptides elicited a significant antigen-specific response
exemplified by IFNg production (P¼ 0.034, P¼ 0.033, P¼ 0.0042 and
P ¼ 0.020; P1-4 respectively) compared with pulsing with pp65 alone
(Fig. 2D).
We next conducted an alanine scanning experiment that is designed
to identify the specific amino acid residues responsible for the peptide's
conformation, stability, and function. Alanine is sequentially substi-
tuted for each nonalanine residue in each of the four peptides. The
corresponding change in epitope activity was measured to identify the
peptide that inducedmaximal immune stimulation ofAPCs. Sixty-one
NP     P1      P2      P3      P4














Human and murine P1 Human P3
Canine  -VVTQDEKRLLNTPASLRCSLQNPEEVLIVTWQKVKPVSLENMVTFSKNHGVVVQPAYKD  118 
Human   QVVTQDEREQLYTPASLKCSLQNAQEALIVTWQKKKAVSPENMVTFSENHGVVIQPAYKD  92 
Mouse   EVVTQDERKALHTTASLRCSLKTSQEPLIVTWQKKKAVSPENMVTYSKTHGVVIQPAYKD  92 
       :******:: * * ***:***:: :* ******* * ** *****:*::****:****** 
Human P2 Human P4 and canine peptide
Canine  KINVTQLELKNSTITFWNTTLEDEGCYKCLFNTFGSGKISGTACLTLSVQPTVFLHYNFF  178
Human   KINITQLGLQNSTITFWNITLEDEGCYMCLFNTFGFGKISGTACLTVYVQPIVSLHYKFS  152 
Mouse   RINVTELGLWNSSITFWNTTLEDEGCYMCLFNTFGSQKVSGTACLTLYVQPIVHLHYNYF  152 



































PP65:    - - +   +    +   +   +   +    +   +    +   +    
P1:         - - - - +   +    - - - - - -
P2:         - - - - - - +   +    - - - -
P3:         - - - - - - - - +   +    - -
P4:         - - - - - - - - - - +   + 
C D
Figure 2.
Targeting CD200ARs stimulates APCs.A,Amino acid sequences of canine, human, andmurine CD200protein showing the homology of the various CD200peptides.
CD14þ cellswere pulsedwith peptides 1–4 and incubated for 48 hours. Nonpulsed cellswere used as a control. Supernatantswere harvested and analyzed for IL1b(B)
and TNFa (C). D, iDCs were pulsed with the CMV antigen pp65 # peptides 1–4. Cells were washed and autologous T cells were added and incubated for another
48 hours. Supernatants were harvested and analyzed for IFNg production. Error bars, SD (n ¼ 3/group; $ , P < 0.05; $$, P < 0.005; $$$ , P < 0.0005 by t test between
treatment groups). Data from cells of three separate healthy donors.
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alanine-substituted peptides were created and purified CD14þ cells
were pulsedwith each peptide to determine their response asmeasured
by cytokine release. This led to the identification of five peptides, P1A8
(designation for peptide, P1, with alanine substitution of the 8th
residue), P2A0, P2A5, P3A12, and P4A10 that stimulated maximal
secretion of inflammatory cytokines by CD14þ cells.
The effects of these peptides on a broader set of immunostimulatory
cytokines, including IL12p70, MIG, and TNF, were then measured in
pulsed CD14þ cells (Fig. 3A). In all instances, significant cytokine
induction was observed after treatment with each of the five peptides.
To further characterize the effect of these peptides on CD14þ cells,
NanoString analysis was performed. Consistent with our previous
observations with murine cells that CD200 exposure suppresses TNF
signaling in APCs and CD200-mimic peptides reverse that effect, the
human peptides, P1A8, P2A0, and P4A10, induced a notable increase in
mRNA expression of cytokines associated with the TNF signaling
pathway (Table 1). These results were recapitulated using a NanoString
platform designed to detect the mRNA expression of TNF-regulated
cytokines (Fig. 3B). The three peptides (P1A8, P2A0, and P4A10) that
consistently induced potent upregulation of mRNA expression of TNF
associated cytokines were-selected for subsequent analysis.
Targeting CD200ARs enhances DC differentiation
The NanoString analysis suggested that stimulation of monocytes


























































































Alanine substitutions enhance antigen-presenting cell stimulation.A,CD14þ cellswere pulsedwith equimolar ratio of peptides, P1A8, P2A0, P2A5, P3A12, and P4A10,
and incubated for 48 hours. Supernatants were harvested and analyzed for IFN1b, IL12p70, MIG, and TNFa production. B, CD14þ cells were incubated with each
peptide for 1 hour and thenRNAwas harvested and analyzed byNanoSight for alterations in immune-related transcripts. Pulsed cellswere normalized to a nonpulsed
(NP) control to derive a heatmap by nSolver using Java Treeview. Cluster analysis of the 35 genes that showed significant expression changes in one or more of the
treated samples when compared to the NP controls (excludes the outlier D1-P3A12). Error bars, SD (n ¼ 3 donors run in triplicate).
Table 1. Pulsed and nonpulsed CD14 cells were analyzed by IPA
analysis for upregulation of the TNF pathway.
Pathways Gene upregulation
LDL oxidation in atherogenesis CCL2, CCL3, ICAM1, IL1B, TNF
Immune response, MIF-mediated
glucocorticoid regulation
ICAM1, IL8, NFKBIA, PTGS2, TNF
EBV LMP1 signaling CCL20, IL8, NFKBIA, TNF
Type II interferon signaling (IFNg) CXCL10, GBP1, ICAM1, IL1B, SOCS3
Cytokines and inflammatory
response
CXCL2, IL1A, IL1B, TNF
Canonical NFkB pathway NFKBIA, TNF, TNFAIP3
IL10 pathway IL1A, IL1B, SOCS3, TNF
IL15 signaling pathways and their
primary biological effects in










CCL2, ICAM1, IL1B, IL8, TNF
TNF signaling pathway CCL2, CCL20, CXCL10, CXCL2,
ICAM1, IL1B, NFKBIA, PTGS2,
SOCS3, TNF, TNFAIP3
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implicated in DC maturation (Table 1). To substantiate this obser-
vation, CD14þ cells isolated from healthy human donors were pulsed
with GM-CSF þ IL4 or one of the peptides, P1A8, P2A0, or P4A10.
These studies demonstrate that hCD200AR-Ls induce the differenti-
ation of CD14 cells into iDCs. This population of cells has decreased
CD14 expression and increased expression of costimulatory mole-
cules, CD80/86 and HLA-DR, compared with cells treated with GM-
CSF þ IL4 (P < 0.0001; Fig. 4A). Moreover, we observed synergistic
upregulation of CD80/86 and HLA-DR when CD14þ cells were
incubated with GM-CSF þ IL4 and each of the peptides (P <
0.0001; Fig. 4B). These results show that P1A8, P2A0, and P4A10
pulsing enhances differentiation of CD14þ monocytes from healthy
donors into iDCs ready for antigen priming.
To assess the effects of the peptides on an antigen-specific response,
GM-CSF þ IL4–induced iDCs were pulsed with the CMV antigen
pp65 with and without an equimolar ratio of P1A8, P2A0, or P4A10.
Autologous T cells were incubated with the iDCs for 48 hours and
IFNg was measured in supernatants. pp65 exposure increased T-cell
IFNg production approximately 4-fold (Fig. 4C). Addition of P1A8,
P2A0, or P4A10 with pp65 induced an additional two- to threefold
increase in IFNg release demonstrating that these peptides can
enhance DC induction of human T-cell antigen-specific response.
We tested the effect of P4A10, themost potent of the three peptides, on
T-cell secretion of inflammatory cytokines after pp65 antigen presen-
tation by dendritic cells. We observed that DCs pulsed with P4A10
induced an increase in secretion of IFNg , IL6, TNFa, and RANTES by
5.4-, 5.6-, 16.6-, and 16.3-fold, respectively, by T cells. Pulsing with a
scrambled peptide as a control failed to enhance the pp65 response
(Fig. 4D). These results show that P4A10 enhanced the ability ofAPCs,
specifically iDCs, to induce a T-cell–mediated immune response.
Validation of the GMP peptide
Because of issues with the stability of P4A10, the peptide that
induced the most potent responses in canine, we opted to produce
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Targeting CD200ARs enhances DC maturation. CD14-purified cells were pulsed with GM-CSFþ IL4 or equimolar ratios of peptide P1A8, P2A0, or P4A10 (A) or GM-
CSFþ IL4with equimolar ratios of peptide P1A8, P2A0, or P4A10 (B) and incubated for 48 hours. Cellswere harvested and phenotyped for CD80, CD86, andHLA-DR.
C, Immature dendritic cells were pulsed with the CMV antigen pp65" equimolar ratios of peptide P1A8, P2A0, or P4A10. Cells were washed and autologous T cells
were added and incubated for another 48 hours. Supernatants were analyzed for IFNg production. D, GM-CSF þ IL4–derived iDCs were pulsed the CMV antigen
pp65" P4A10. Cells were washed, autologous T cells were added and incubated for another 48 hours. Supernatants were analyzed for IFNg , IL6, TNFa, and RANTE.
Error bars, SD (n ¼ 3 donors each run in triplicate; $, P < 0.05; $$ , P < 0.005; $$$ , P < 0.0005 by t test).
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P1A8 for translation into a phase I clinical trial in patients with
GBM. The murine correlate of P1A8 showed the greatest efficacy in
our murine survival model. To insure the GMP-grade peptide
retained activity following production and formulation for vialing,
we compared its binding kinetics to that of the murine peptide to
HEK293 cells and showed no significant differences (Fig. 5A).
Next, we tested the GMP peptide using a human CMV model
to assess an anti-pp65 response and demonstrated that the
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Validation of the GMP peptide. A,
HEK293 cells were pulsed with the
murine P1A12 and human P1A8 fluo-
rescently labeled CD200AR-L and
analyzed for binding. B, GM-CSF þ
IL4–derived iDCs were pulsed the
CMV antigen pp65 " P1A8. Cells were
washed, autologous T cells were
added back, and incubated for a fur-
ther 48 hours. Supernatantswere ana-
lyzed for IFNg production. CD14þ cells
were pulsed with different concentra-
tions of P1A8 and analyzed for MCP-1
(C) and IL8 production (D). Cells
were normalized to nonpulsed cells
(n ¼ 3 donors run in triplicate; $ , P <
0.05; $$ , P < 0.005; $$$ , P < 0.0005 by
t test).
A CD14 Cells B CD14 Cells






















































Nonpulsed      CD200AR-L Nonpulsed          CD200AR-L
C CD14 Cells D CD14 Cells
***
Figure 6.
Inhibitory receptor, CD200R1, is down-
regulated by CD200AR-L. CD14þ cells
were pulsed with CD200AR-L and ana-
lyzed for changes in CD200R1 transcrip-
tion (A) and protein levels by flow cyto-
metry (B). CD14þ cells were pulsed with
CD200AR-L and analyzed for changes in
PD-1 transcription (C) and protein levels
(D) by flow cytometry (n¼ 3 donors run
in triplicate; $ , P <0.05; $$ , P <0.005; $$$ ,
P < 0.0005 by t test).
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manufactured peptide maintained its ability to enhance an antigen-
specific response (Fig. 5B). Finally, we assessed the binding
kinetics of the GMP-grade peptide to CD14 cells and found a
dose response of cytokine induction that peaked at approximately
1,500 mmol/L (Fig. 5C and D). The results from all of these
experiments confirm maintenance of immunostimulatory activity
of the GMP-grade peptide.
APCs primed with P1A8 downregulate the expression of
CD200R1
We have demonstrated that targeting CD200ARs activates the
immune system, in part, by overpowering the suppressive effects of
CD200. To gain a better understanding of this mechanism, we pulsed
human CD14 cells with GMP-grade P1A8. In Fig. 6A and B, we show
that this treatment decreased the expression of the inhibitory receptor,
CD200R1. Therefore, APCs in the draining lymph nodes or glioblas-
tomamicroenvironment that have been exposed to our peptide should
be resistant to the effects of soluble CD200 from the tumor. This
suppression was not observed in mock-treated control reactions.
Interestingly, downregulation of PD-1 on APCs was also observed
(P ¼ 0.005; Fig. 6C and D). These results open the possibility of
overcoming CNS immunosuppression through modulation occurring
outside of the CNS.
Discussion
Immune checkpoint inhibitors are currently at the forefront of
developing immunotherapies (22, 23). The most clinically successful
have been those against CTL-associated protein 4 (CTLA4), pro-
grammed cell death 1 receptor (PD-1) and its ligand, programmed
cell death ligand 1 (PD-L1). However, tumors can inhibit the antitu-
mor immune response throughmultiple checkpoints hindering the use
of these inhibitors as monotherapy. This is particularly critical for
high-grade malignant brain tumors with a relatively low mutational
burden and/or low immunogenicity. Therefore, multiple checkpoint
inhibitors are often used concomitantly to enhance survival, but this
practice frequently causes serious immune-related adverse
events (6, 7).
Currently, no single FDA-approved checkpoint inhibitor has dem-
onstrated significant efficacy in patients with high-grade glioma. Here,
we explore an alternate paradigm of immune checkpoint inhibition at
the site of autologous tumor vaccine inoculation outside of the CNS.
Our previous studies provided compelling evidence that the CD200
immune checkpoint protein in tumor lysate suppresses the ability of
APCs to trigger an effective antitumor immune response through
locally recruited T cells (10, 12).
Several rigorous studies have provided evidence that targeting the
CD200 checkpoint enhances immunotherapy (24–28). In the most
advanced of these studies, a mAb against CD200, ALXN6000, was
evaluated in a clinical trial (NCT00648739) initiated in 2008 for
patients with relapsed or refractory B-cell chronic lymphocytic
leukemia (B-CLL) and multiple myeloma. The results of this study
that was terminated before completion were recently published that
showed some efficacy of ALXN6000 treatment in patients with
B-CLL, but progressive disease in all patients with multiple
myeloma (29).
We believe that there are problems associated with the use of an
anti-CD200 antibody for GBM, some of which are exemplified by
the Alexion results: (i) antibodies fail to cross the blood–brain
barrier, which limits their efficacy in CNS tumors; (ii) multiple cells
including neurons and immune cells express CD200 (30, 31); there-
fore, the use of an anti-CD200 antibody might cause off-target
toxicity and decrease effectiveness. Alexion reported that in patients
with B-CLL, 95% of the patients with B-CLL had as much as a 98%
reduction of CD200þCD4þ T cells. The loss of these immune cells
may create an immunocompromised condition and may be the
reason that only one achieved a durable partial response while most
of the patients had stable disease. Although they reported CD200
expression on B-CLL cells was greatly reduced in 67% of patients,
CD200 is secreted from tumors (32) and this parameter does not
correlate with tumor reduction.
We chose to develop peptide ligands to target the CD200-
activating receptors on APCs. Peptides have the ability to penetrate
further into tissue (33) and have higher activity per unit mass,
greater stability, and reduced potential for nonspecific binding that
may result in decreased toxicity (34). Despite having clearly dem-
onstrated clinical efficacy of a synthetic peptide ligand, the mech-
anism that modulated an immune response through activation
receptor binding was unknown. We developed three murine
CD200AR-Ls that demonstrated different survival rates in a murine
glioma model. The murine ligand, P1, that was predicted to bind
primarily to CD200AR4 enhanced survival in our murine glioma
model, whereas other ligands predicted to bind primarily to
CD200AR2 and CD200AR3 enhanced survival in our murine breast
tumor model, but had no efficacy in the glioma model (12). Because
our interest was primarily in the role of activation receptors
(CD200ARs), we focused cell lines expressing CD200AR2–4. We
observed that cells expressing certain CD200AR combinations,
specifically 2&3 and 3&4, responded to stimulation by the P1
ligand. In contrast, cells expressing other receptor combinations,
including 1, 2, and 3, 1, 3, and 4, or 2, 3, and 4, failed to bind P1 and
had no increase TNFa production, and the CD200AR2&4 cell line
bound P1, but had no concomitant increase TNFa production. We
suggest that ligation of the various ARs produces different immune
responses, a phenomenon that is currently under investigation in
our laboratory. These data lead to the hypothesis that the activation
receptors (CD200ARs) function as complexes to modulate immune
activation. This could explain our observation that targeting dif-
ferent CD200ARs induced different survival benefits in our breast
carcinoma and glioma murine models (12).
Our studies provide compelling data that the presence of the CD200
protein in brain tumor lysates suppresses the capacity of local APCs to
activate recruited T cells and trigger an effective antitumor immune
response (10, 12). We built on this earlier observation and tested
peptides in an attempt to target CD200-mediated immunosuppression
and successfully reversed the immunosuppressive effect of CD200 in
murine studies.
While murine brain tumor models have yielded valuable insights
into the etiology of glioblastoma, the vast majority of novel therapies
that showed enormous promise in these models subsequently failed in
clinical studies. Recent attention has been focused on companion dogs
as a translational model due to their strong anatomic and physiologic
similarities to humans and the sheer number of pet dogs that are
diagnosed and managed with cancer each year (35–37). Strong sim-
ilarities have been shown between the canine and human genome,
especially with respect to gene families associated with cancer. These
combined factors suggest cancer in companion dogs as a viable model
for preclinical human cancer research including brain tumors (38–40).
Because of our success in the canine CD200 trial (41), the human
CD200AR-L, P4A10, most analogous to the canine CD200AR-L, was
initially selected for a human phase I trial. However, the charges within
this peptidemade it difficult to scale up for GMP production, therefore
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we chose P1A8, analogue of the murine peptide that provided the
greatest survival benefit in our murine studies. Our human in vitro
studies demonstrated that hP1A8 enhanced DC differentiation, mat-
uration, and cytokine production, as well as an antigen-specific T-cell
response. In addition to cell activation, we also demonstrated down-
regulation of the inhibitory receptor, CD200R1. This is important
because CD200 secreted by the tumor suppresses the ability to mount
an antitumor response due to binding ofCD200/CD200R1 on immune
cells and CD200 is upregulated in the tumor-associated vascular
endothelium (as evidenced in our earlier studies; ref. 10) limiting
the ability of immune cells to extravasate into the tumor microenvi-
ronment in response to immunotherapy. We believe downregulation
of CD200R1 will allow immune cells to move into the tumor micro-
environment from the tumor vasculature. Moreover, the downregula-
tion of both CD200R1 and PD-L1 should render immune cells
resistant to tumor-induced suppression in the tumor microenviron-
ment.We hypothesize that the significant survival response seen in the
canine preclinical trial is due to the ability of the CD200AR-L peptide
to override the suppressive effects of multiple immune checkpoints.
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